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NOVEL MECHANISMS OF β-ADRENERGIC SIGNLING IN PROSTATE CANCER 
PROGRESSION 
By 
Mohit Hulsurkar, MS 
Advisory Professor: Wenliang Li, Ph.D.  
 
Prostate cancer is the second leading cause of cancer death among 
American men. The American Cancer Society estimates that 180,890 men will be 
will be diagnosed with prostate cancer in 2016 in the USA. 
(http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-
statistics). Androgen deprivation therapy (ADT) is the standard treatment for early 
stage prostate cancer. But most patients relapse with aggressive variants of prostate 
cancer, with survival time between 1-3 years. In order to develop cure for such 
aggressive variants of prostate cancer, our present understanding of the 
mechanisms underlying its progression needs to be advanced.   
Recently, it has been found that activation of β-adrenergic signaling pathway 
leads to aggressive variants of prostate cancer. β-adrenergic signaling involves the 
activation of β-adrenergic receptors (ADRBs), eventually leading to increased 
activation of cAMP response element-binding protein (CREB). Downstream targets 
of CREB activation in neuroendocrine differentiation as well as in neoangiogenesis 
are largely unknown, indicating that the underlying mechanisms of β-adrenergic 
signaling in prostate cancer progression are far from completely understood. For 
instance, while the epigenetic regulation by histone deacetylases 2 (HDAC2) is 
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necessary for stress to induce cardiac hypertrophy, its mechanism are unknown in 
cancer progression. Similarly, another regulator of β-adrenergic signaling, GRK3 
was recently shown to be a new critical regulator of prostate cancer progression and 
tumor angiogenesis. However, mechanisms of GRK3 in prostate cancer progression 
and its regulation by ADRB2 signaling remain unknown.  
Our hypothesis is that GRK3 and HDAC2 are critical downstream effectors 
of β-adrenergic signaling-activated CREB in promoting prostate cancer progression. 
Here, we show that CREB directly activates GRK3 transcription by binding to its 
promoter and this up-regulation of GRK3 expression by ADRB2/CREB pathway is 
sufficient as well as necessary to induce the neuroendocrine differentiation of 
prostate cancer cells. We also show that downstream of chronic stress and ADRB2, 
CREB binds to HDAC2 promoter and activates its expression. HDAC2 further 
suppresses the expression of thrombospondin 1 (TSP1) in order to induce 
angiogenesis, thus acting as a mediator for the β-adrenergic signaling pathway.  
Here, we have introduced two new pathways acting downstream of the 
ADRB2/CREB axis. We show that the CREB/GRK3 axis leads to neuroendocrine 
prostate cancer progression. We have introduced a new paradigm that β-adrenergic 
signaling and epigenetic gene expression regulation may be working synergistically 
resulting in cancer progression.  
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Prostate Cancer Progression 
Prostate cancer (PCa) is the second most common cancer and second leading 
cause of cancer related death in American men 
(http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-
statistics). The American Cancer Society estimates in 2016, about 180,890 new 
patients will be detected and about 26,120 deaths from prostate cancer will occur in 
the US (http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-
key-statistics). Worldwide, around 300,000 men died of prostate cancer in 2012 and 
this number is estimated to be 630,000 in 20351. Prostate-specific antigen (PSA) 
screening is evolving constantly and is helping in the early detection of prostate 
cancers. According to a recent study, more than 80% of the patients detected via 
PSA screening showed non-metastatic, localized prostate cancers2. Early detection 
aids in the treatment of prostate cancer with radical prostactomy, which controls the 
localized cancer in most men3. However, cancer recurs in most of the patients (Fig. 
1.1) and is associated with rising PSA levels. At this stage of disease, androgen 
deprivation therapy (ADT) is prescribed with medical or surgical castration being the 
standard practice. Ever since the dependence of prostate cancer on androgen was 
demonstrated by Huggins et al. in 19414-6, ADT by castration is being used to treat 
prostate cancers. Castration results into low blood testosterone levels (< 50 ng/dL) 
and leads to cell apoptosis as well as inhibition of prostate cancer progression. 
However, the disease becomes resistant to ADT and evolves into castration 
resistant prostate cancer (CRPC). 
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Figure 1.1 Prostate cancer progression with time. A model depicting different 
stages of prostate cancer in patients with time and available therapy. Developed 
based on the model from Ramalingam S, Pollak KI, Zullig LL, Harrison MR. What Should 
We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis? 
Oncology (Williston Park). 2015 Sep;29(9):680-5, 687-8, 694. 
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Targeting the androgen receptor (AR) is a standard course of action at early stages 
of CRPC, when the disease is still non-metastatic. However, most patients relapse 
with aggressive variants of prostate cancer, resistant to currently available therapies 
and show metastasis into bones, lymph nodes, lungs and liver7. At this stage, the 
prognosis of disease is poor, with survival time between 1-3 years8-16.  
In order to develop cure for such aggressive variants of prostate cancer, our present 
understanding of the mechanisms underlying its progression needs to be advanced.   
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Prostate cancer progression and β-adrenergic signaling 
It has been found recently that in addition to androgen deprivation therapy and 
exposure to ionizing radiation, activation of the β-adrenergic signaling pathway also 
leads to aggressive variants of prostate cancer17,18. Interestingly, β-adrenergic 
signaling has been found to be responsible for the progression of breast19, colon and 
pancreatic20, lung21, skin22, ovarian23 cancers. Furthermore, inhibition of β-
adrenergic signaling by β-blockers, a group of drugs used to treat multiple conditions 
such as hypertension and cardiac arrhythmia, is reported to have better cancer 
prognosis24-34. According to epidemiological studies, cancer patients using β-
blockers showed reduced cancer related mortality in prostate26,33,34, ovarian, and 
non-small cell lung cancers25. In breast cancer patients, it was associated with 
reduced metastasis, disease free survival, cancer recurrence and mortality30-32. 
Based on these epidemiological studies, phase II clinical trials are underway to study 
the effects of a β-blocker, propranolol, on the progression of ovarian, cervix, 
colorectal, and breast cancers (ClinicalTrials.gov identifiers: NCT01504126, 
NCT01308944, NCT01902966, NCT00888797, and NCT01847001). However, no 
clinical trials are being conducted to study the effects of propranolol in prostate 
cancer, indicating that studying the mechanisms of β-adrenergic signaling could lead 
to development of a novel therapy to inhibit prostate cancer progression.  
β-adrenergic signaling involves the activation of β-adrenergic receptors (ADRBs) by 
epinephrine and norepinephrine, catecholamines that mediate body’s fight or flight 
response35. Expression of ADRBs is high in the normal prostate, especially ADRB2, 
which is highly expressed in the luminal cells36-39. ADRB2 is predominantly 
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expressed in the epithelial cells in normal as well as malignant tissues40,41 and its 
expression is up-regulated in prostate cancer at mRNA level40,42 as well as at protein 
level40,41,43. However, expression of ADRB2 was reported to be down-regulated 
following castration and androgen deprivation40,44, indicating that the mechanisms 
involved in ADRB2 signaling need to be studied further to better understand its role 
in prostate cancer progression.  
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β-adrenergic signaling and neuroendocrine prostate cancer 
Because of its role in transducing the signals of sympathetic nervous system, 
activation of β-adrenergic receptors is widely considered to be responsible for the 
onset of neuroendocrine differentiation of prostate adenocarcinoma cells45-48. 
Neuroendocrine prostate cancer (NEPC) is an aggressive variant that causes 
around 25% of the prostate cancer deaths49-52. It is resistant to currently available 
therapies and the survival period is less than a year8-16. NEPC onset is considered 
as a mechanism by which cancer cells resist the androgen deprivation therapy53-55 
and with the use of more potent androgen deprivation drugs, NEPC incidence is 
expected to rise56-59. 
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β-adrenergic signaling and neoangiogenesis 
Dr. Judah Folkman reported his ‘tumor angiogenesis hypothesis’ in 1971 stating that 
tumor growth is correlated with neovascularization and without angiogenesis, tumor 
growth would be restricted to microscopic size60,61 (Fig. 1.2). His pioneering 
research created interest in studying tumor angiogenesis, lead the eventual 
discovery of VEGF, originally hypothesized as tumor angiogenesis factor (TAF), and 
has resulted into development of antiangiogenic drugs62,63. Hanahan and Weinberg 
have reported induction of angiogenesis to be one the six hallmarks of cancer64,65 
(Fig. 1.3).  It is now well established that the solid tumors need supply of nutrients 
and oxygen as well as removal of metabolite waste, which is provided by formation 
of new capillaries.  
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Figure 1.2 Folkman model of tumor angiogenesis. Illustration of the concept that 
most solid tumors may exist early as tiny cell populations living by simple diffusion in 
the extracellular space (further growth requires vascularization, and the tumor then 
maintains itself by perfusion). Tumor-angiogenesis factor (TAF) may be the mediator 
of neovascularization. 
Reproduced with permission from Folkman J. Tumor angiogenesis: therapeutic 
implications. N Engl J Med. 1971 Nov 18;285(21):1182-6., Copyright Massachusetts 
Medical Society.  
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Figure 1.3 The Hallmarks of Cancer Acquired capabilities of cancer. We suggest 
that most if not all cancers have acquired the same set of functional capabilities 
during their development, albeit through various mechanistic strategies. 
 
Reproduced with permission from Douglas Hanahan, Robert A Weinberg. The 
Hallmarks of Cancer: The Next Generation. Cell, Volume 144, Issue 5, 2011, 646-
674. http://dx.doi.org/10.1016/j.cell.2011.02.013 
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In normal physiological conditions in adults, angiogenesis is turned on only 
transiently. However, in tumors, it is usually on and results into sprouting of new 
capillaries accompanied by tumor growth.  
Induction of angiogenesis is another mechanism through which β-adrenergic 
signaling is considered to promote cancer progression. Its activation by chronic 
behavioral stress results into up-regulation of VEGF expression and increased 
angiogenesis in ovarian carcinoma23. Furthermore, in LNCaP and PC3 cells, 
activation of ADRB2 by epinephrine and norepinephrine respectively resulted into 
increased VEGF expression66,67. Interestingly, inhibition of ADRB2 by β-blocker 
propranolol resulted into reduced blood vessel volume in rats68, supporting the 
observation that activation of β-adrenergic receptors results into increased tumor 
angiogenesis in the prostate. However, another study reported no up-regulation in 
VEGF expression upon activation of β-adrenergic signaling by chronic stress18, 
indicating that β-adrenergic signaling might induce angiogenesis through other 
mechanisms as well.  
Interestingly, neuroendocrine cells are found to be the primary source of 
VEGF in the prostate69. Also, the number of neuroendocrine cells is shown to 
correlate positively with neo-angiogenesis in prostate cancers70,71. Furthermore, 
multiple factors that promote the neuroendocrine differentiation are also known to 
promote angiogenesis17, indicating that these two processes are correlated, with 
ADRB2 being the putative upstream regulator.  
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Downstream mechanisms of β-adrenergic signaling in prostate cancer  
Activation of ADRBs leads to increased adenylyl cyclase activity and elevated 
cAMP levels (Fig. 1.4). cAMP then binds to the cAMP binding domain (CBD) of 
protein kinase A (PKA) and exchange proteins directly activated by cAMP (EPAC1 
and EPAC2)72-75. Epac is known to activate Rap1, independent of PKA. Depending 
upon their relative abundance, distribution and localization, as well as the specific 
cellular environments, Epac and PKA may act independently, converge 
synergistically, or oppose each other in regulating a specific cellular function76. Upon 
activation of PKA by cAMP, its catalytic subunit is released and is considered to 
primarily bind to cAMP response element-binding protein (CREB) and phosphorylate 
it at S133. CREB is a transcription factor, which leads to activation of transcription of 
multiple genes. Recently, the cAMP/PKA pathway was shown to phosphorylate 
BCL2-associated agonist of cell death (BAD) leading to stress mediated resistance 
to apoptosis in prostate cancer cells18,77. Activated PKA also inhibits the RhoA-
ROCK pathway, leading to cytoskeletal remodeling and neurite outgrowth78. Another 
signaling cascade targeted by activated PKA is the PI3K/AKT pathway, which leads 
to up-regulation of VEGF in HIF-1α dependent manner66.  
Activation of cAMP/PKA pathway upon stimulation of ADRB2 by its agonists 
is known to induce neuroendocrine differentiation46,47. Increased cAMP activity in 
prostate cancer cells LNCaP, PC3 and PC3M leads to neuroendocrine 
differentiation45,47,79-81 and overexpression of constitutively active PKA is sufficient to 
promote the neuroendocrine differentiation of LNCaP cells46. Conversely, elevated 
cAMP activity was unable to induce the neuroendocrine differentiation upon 
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overexpression of inactive mutant of PKA47. Activated PKA phosphorylates cAMP 
response element-binding protein (CREB) at S133 and activates it46,47,82,83.  
 
Figure 1.4 Downstream mechanisms of β-adrenergic signaling. Activation of 
ADRB results into increased cAMP levels, which activates EPAC and PKA that 
further regulate multiple signaling pathways.  
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Suppressing this cAMP/PKA induced activation of CREB inhibits the induction of 
neuroendocrine differentiation46,47,82-86, suggesting that downstream of ADRB2, the 
cAMP/PKA/CREB pathway leads to neuroendocrine differentiation. Interestingly, 
activation of this pathway by chronic behavioral stress is found to induce tumor 
angiogenesis in mouse models of ovarian cancer23. Thaker et al. found that VEGF 
expression was up-regulated upon activation of the ADRB2/cAMP/PKA/CREB 
pathway. However, it was not clear whether CREB, a transcription factor, induces 
VEGF expression directly.  
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Objective and hypothesis of dissertation  
Downstream targets of CREB activation in neuroendocrine differentiation as well as 
in neoangiogenesis are largely unknown, indicating that the underlying mechanisms 
of ADRB2 signaling in prostate cancer progression are far from completely 
understood. For instance, epigenetic regulation by histone deacetylases (HDACs) is 
necessary for stress to induce cardiac hypertrophy87-89. Specifically, HDAC2 has 
been implicated as a key mediator in this process90.  However, it is unknown if and 
how ADRB2 signaling directly regulates HDAC2 activity. Furthermore, the 
involvement of HDAC2-mediated epigenetic regulation in ADRB2-promoted cancer 
progression also remains unclear. Another regulator of ADRB2, GRK3, a kinase that 
phosphorylates ADRB2, was recently shown to be a new critical regulator of prostate 
cancer progression and tumor angiogenesis91. It is necessary for the survival and 
proliferation of metastatic cancer cells, and sufficient to promote primary tumor 
growth in prostate. Notably, GRK3 is overexpressed in human prostate tumors, 
especially in soft tissue metastases91. However, role of GRK3 in NEPC progression 
and its regulation by ADRB2 signaling remain unknown.  
We have studied the role of GRK3 and HDAC2 in promoting prostate cancer 
progression, downstream of ADRB2 signaling. We have investigated whether stress 
activated β-adrenergic signaling modulates HDAC2-mediated epigenetic regulation 
to promote prostate cancer progression.  To understand how GRK3 and NEPC 
progression contribute to poor prognosis in prostate cancer, we have investigated 
the mechanisms of GRK3 overexpression in prostate cancer and its connections to 
ADT, CREB activation and NEPC development. We have also studied whether and 
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how the ADRB2/cAMP/PKA/CREB pathway regulates the expressions of GRK3 and 
HDAC2.  
Our hypothesis is that GRK3 and HDAC2 are critical down-stream effectors of 
β-adrenergic signaling-activated CREB in promoting prostate cancer progression. 
Fig. 1.5 demonstrates our proposed working model. To test our hypothesis, I have 
divided my dissertation into two parts: i) to study the regulation of GRK3 expression 
and its role in NEPC progression downstream of ADRB2 signaling, and ii) to study 
the regulation of HDAC2 expression and its role in ADRB2 signaling promoted 
prostate cancer progression and increased tumor angiogenesis.  
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Figure 1.5 Our hypothesis is that GRK3 and HDAC2 are critical down-stream 
effectors of β-adrenergic signaling activated CREB in promoting prostate cancer 
progression. Activated by cAMP binding, PKA phosphorylates and activates CREB, 
which eventually binds to GRK3 and HDAC2 promoters and activates their 
expression. Overexpression of GRK3 and HDAC2 eventually leads to cancer 
progression.  
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Here, we show that CREB directly activates GRK3 transcription by binding to its 
promoter and this up-regulation of GRK3 expression by ADRB2/CREB pathway is 
sufficient as well as necessary to induce the neuroendocrine differentiation of 
prostate cancer cells (Fig. 1.6). We also show that downstream of ADRB2, CREB 
binds to HDAC2 promoter and activates its expression. HDAC2 further suppresses 
the expression of thrombospondin 1 (TSP1) in order to induce angiogenesis, thus 
acting as a mediator for the β-adrenergic signaling pathway (Fig. 1.6).  
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Figure 1.6 Our hypothesis is that GRK3 and HDAC2 are critical down-stream 
effectors of β-adrenergic signaling activated CREB in promoting prostate cancer 
progression. Activated by cAMP binding, PKA phosphorylates and activates CREB, 
which eventually binds to GRK3 and HDAC2 promoters and activates their 
expression. Overexpression of GRK3 leads to neuroendocrine prostate cancer 
progression, while HDAC2 overexpression eventually leads to increased 
angiogenesis and cancer progression through TSP1 suppression. 
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Chapter Two:  
Materials and Methods 
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Cell culture  
PC3 prostate cancer cells used in this study are a poorly metastatic variant that was 
kindly provided by Dr. Isaiah Fidler91,92 and were confirmed to match with the PC3 
cells from ATCC by DNA finger printing. Mouse endothelial cells SVEC4-10, kindly 
provided by Dr. Vihang Narkar, were originally ordered from ATCC. SVEC4-10 cells 
were cultured in DMEM (Mediatech), with 10% FBS and 1% penicillin-streptomycin. 
ADT-induced NEPC cells NE1.3 were maintained in phenol red-free RPMI 1640 
medium supplemented with 5% charcoal-striped FBS (Gibco) and 1% penicillin and 
streptomycin93. Prostate neuroendocrine small cell carcinoma cells NCI-H660 were 
obtained from ATCC and cultured according to ATCC guidance. VCaP cells were 
maintained in the DMEM medium supplemented with 10% FBS (Gibco), 1% 
glutamine, 1% penicillin and streptomycin.  RWPE-1 cells were grown in 
keratinocyte serum free medium with 0.05 mg/ml BPE and 5 ng/ml EGF, according 
to ATCC guidance. Cultures were grown in a 37°C incubator with 5% CO2. All other 
prostate cancer cell lines were purchased from ATCC and were cultured in RPMI 
1640 media (Mediatech), supplemented with 10% FBS (Gibco) and 1% penicillin-
streptomycin (Mediatech). 
 
Animal experiments  
NOD/SCID mice were purchased from Charles River Laboratories. All the mouse 
procedures were approved by the Animal Care and Use Committees of UTHealth 
and performed in accordance with institutional polices (Protocol # AWC 14-050). 
One million PC3 or LNCaP cells expressing luciferase were injected subcutaneously 
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on the flanks and shoulders of NOD/SCID mice. In the stress experiment, the mice 
were subjected to behavioral stress by restricting the movements for one hour, twice 
a day. In the chemical treatment experiments, the control group received buffered 
saline, the ‘ISO’ group received 10 mg/kg isoproterenol, twice a day. In each 
experiment, all the mice were sacrificed when mice with the biggest tumors reached 
the humane endpoint (1 cm diameter). The luciferase signal from the xenograft 
tumors was measured with IVIS Lumina II platform machine (Caliper Life Sciences).   
 
Vector constructs and virus preparation  
All shRNA constructs are in pLKO.1 vector and were purchased from Sigma-Aldrich. 
TRCN 6321 and TRCN7086 shRNAs were used to downregulate HDAC2 and were 
packaged into viral particles using 293T cells94, according to previously described 
method91. PC3 cells were transfected with mammalian expression vector pcDNA3.1, 
Flag-pcDNA3.1-CREB-WT (wild type), or Flag-pcDNA3.1-CREB-Y134F95 (kindly 
provided by Dr. Rebecca Berdeaux) using TransIT-LT1 transfection reagent and 
selected with 400μg/ml of G418. 
 
cDNA/shRNA transduction and transfection in prostate cancer cells 
LNCaP cells expressing GFP, GRK3 (wild type cDNA) or GRK3-KD (kinase dead 
cDNA) were generated through retroviral transduction as previously described91. 
Preparation and usage of shGRK3 lentivirus have also been described91. LNCaP 
and NE1.3 cells were infected by shGRK3 lentivirus at MOI of 5 in the presence of 
polybrene (8 μg/ml). shScramble was used as control. PC3 cells were transfected 
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with the mammalian expression vector pcDNA3.1, Flag-pcDNA3.1-CREB (wild type), 
Flag-pcDNA3.1-CREB (Y134F)95 (kindly provided by Dr. Rebecca Berdeaux at UT-
Houston) using TransIT-LT1 transfection reagent (Mirus, Madison, WI, USA). 
Transfected PC3 cells were selected with 400μg/ml of G418. 
 
Western blotting analysis   
Western blotting analysis was carried out as previously described91. Primary 
antibodies used were as follows:  
anti-GRK3 (3460-1 Epitomics, USA), anti-TSP1 (ab1823, Abcam), anti-p-CREB 
(#9198, Cell Signaling Technology), anti-CREB (#9197, Cell Signaling Technology), 
anti-HDAC2 (#2545, Cell Signaling Technology), and anti-actin (SC47778, Santa-
Cruz Biotechnology).  
After washes, the membranes were incubated with HRP-conjugated secondary anti-
mouse or anti-rabbit antibodies (Cell Signaling Technology) for 1 h at room 
temperature. Finally, the immunoreactive bands were developed with Pierce ECL 
Western Blotting Substrate (Thermo Scientific) on Blue Basic autoradiography Film 
(Bioexpress).  
 
Immunofluorescence (IF) and immunohistochemistry (IHC) staining 
IF staining was carried out as previously described96. Primary antibodies used were 
as follows: anti-TSP1 (ab85762, Abcam) and anti-IB4 (B-1205, Vector Labs). IHC 
staining procedure was similar to that we previously described96,97. Briefly, slides 
with 5-μm sections of formalin-fixed, paraffin-embedded xenograft tumors were 
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deparaffinized, rehydrated and subjected to antigen retrieval with 10 mM sodium 
citrate pH 6.0 for 40 min. Slides were then incubated with hydrogen peroxide as 
Peroxidase Suppressor (Thermo Scientific Pierce) and 2.5% horse serum as 
blocking buffer, followed by incubation with CD31 primary antibody (ab28364, 
Abcam) overnight at 4°C, PBS washes and then HRP conjugated secondary 
antibody 1 h at room temperature. The immunohistochemistry reaction was 
developed with a DAB substrate Kit (Vector Labs), slides were counterstained with 
hematoxylin and mounted in VectaMount permanent mounting medium (Vector 
Labs).  
 
Immunohistochemistry staining on human prostate tumor tissue microarray  
The Universal Elite ABC kit (Vector Labs) was used for immunohistochemistry (IHC) 
staining, according the manufacturer’s instructions. Briefly, slides of five micrometer 
sections from 78 cases of formalin-fixed and paraffin-embedded prostate cancer and 
normal tissue blocks were dewaxed in 60°C oven for 2 hours and rehydrated 
through incubating in xylene and alcohol series. Antigen retrieval was done in 10 
mM sodium citrate buffer (pH 6.0) in a food steamer for 30 minutes. After 
suppressing the endogenous peroxidase activity the sections were incubated in 
normal horse serum to prevent nonspecific immunoglobulin binding. Upon PBS 
wash, the sections were then treated with the anti-human p-CREB (Cell Signaling 
Technology) or anti-human GRK3 antibody (Epitomics) at 4°C overnight. A 
streptavidin-HRP detection system was used to reveal specific binding. 
Immunoreactivity was scored as following: staining intensity -/+, <25% positive cells 
 
 
25 
 
(weak, score 1); staining intensity ++, 25-50% positive cells (intermediate, score 2); 
and staining intensity +++, >50% positive cells (strong, score 3). Percent of positive 
cells and staining intensity were scored independently by two experienced 
researchers.  
 
Reverse transcription and quantitative PCR analysis  
TRIzol (Invitrogen) was used to isolate RNA from cells. cDNA was generated by 
reverse transcription with iScript cDNA Synthesis Kit (Bio-Rad). Real time PCR was 
performed using SsoFast EvaGreen Supermix (Bio-Rad) in Bio-Rad CFX96 Real-
Time PCR Detection System using the following primers:  
HDAC2-F: cagatcgtgtaatgacggtatca, HDAC2-R: ccttttccagcaccaatatcc; TSP1-F: 
caatgccacagttcctgatg, TSP1-R: tggagaccagccatcgtc, GRK3-F: gcagtgccgactggttct,  
GRK3-R: gtctgaaagggctgtgacct, CREB-F: ggagcttgtaccaccggtaa, CREB-R: 
gcatctccactctgctggtt, CHGA-F: tacaaggagatccggaaagg, CHGA-R: 
ccatctcctcctcctcctct, CHGB-F: cacgccattctgagaagagc, CHGB-R: 
tctcctggctcttcaaggtg, ENO2-F: ctgtggtggagcaagagaaa, ENO2-R: 
acacccaggatggcattg, AR-F: gccttgctctctagcctcaa, AR-R: ggtcgtccacgtgtaagttg, PSA-
F: cacagcctgtttcatcctga, PSA-R: atatcgtagagcgggtgtgg, GAPDH-F: 
agccacatcgctcagacac, and GAPDH-R: gcccaatacgaccaaatcc.  
 
For all RT-PCR analysis, GAPDH was used to normalize RNA input and expression 
levels were calculated according to the comparative CT method (ΔΔCT).  
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Chromatin Immunoprecipitation (ChIP) 
Cells treated with ISO or ISO+PRO were crosslinked with formaldehyde and lysed in 
SDS lysis buffer. Cell lysate was sonicated on ice, for 12 cycles of 20 sec ON and 40 
sec OFF at 40% amplitude using Branson Low Power Ultrasonic Systems 2000 
LPt/LPe sonicator (Fisher Scientific) and the supernatant was used for ChIP 
experiments with anti-CREB (# 06-863, Merck Millipore), anti-p-CREB (# 9198, Cell 
Signaling Technology), anti-HDAC2 (ab51832, Abcam) or negative control IgG. The 
immunoprecipitates were washed sequentially with low salt buffer, high salt buffer, 
LiCl buffer and finally TE buffer. DNA was eluted and the reversal of crosslinking 
was done with proteinase-K and 0.2 M NaCl. The DNA was extracted using phenol 
chloroform and PCR was conducted using the following primers:  
 
GRK3-CREB-F: GCCTCTAAGATCACCCAGCA, GRK3-CREB-R: 
AGACCTGACATCTGCCTACA, HDAC2-CREB-F: CATTGCTGCAGAGTGGAACA 
HDAC2-CREB-R: AGGTGGAGGCAGATTAAGGA, TSP1-HDAC-F: 
GTCATACAACACTCCCACGC and TSP1-HDAC-R: 
CCAGGGCATAGGTAGAAGCT.  
 
Endothelial cell migration assay 
PC3 cells were treated as indicated overnight in RPMI-1640 with no serum. SVEC4-
10 cells were grown till 70% confluence, starved overnight, trypsinized and 
resuspended in the conditioned media collected from PC3 cells. 50,000 SVEC4-10 
cells were seeded per Boyden chamber insert (8 μm, BD Biosciences). Cells were 
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allowed to migrate for 4 hours and the inserts were fixed and stained with crystal 
violate dye to observe migrated cells. Cell migration was analyzed qualitatively.  
 
Endothelial cell tube formation assay 
PC3 cells were treated as indicated overnight in RPMI-1640 with no serum. SVEC4-
10 cells were starved overnight, trypsinized and resuspended in the conditioned 
medium from PC3 cells. 20,000 SVEC4-10 cells/well in PC3 conditioned medium 
were seeded on the Matrigel. Pictures were taken under 4X and 10X magnification 
and the number of branches in SVEC tube formation were quantified. 
 
Microarray data mining 
The indicated GSE microarray data sets were downloaded from the GEO database 
http://www.ncbi.nlm.nih.gov/gds.The TCGA_PCa data on CREB and GRK3 were 
downloaded from http://www.cbioportal.org42,98. The normalized and transformed 
gene expression values from the sources were used in our analysis and statistical 
calculation.  
 
Statistical analyses 
P-values were obtained through Student’s t-test, unless otherwise indicated. 
Spearman correlation coefficient and associated P-values for gene expression from 
public datasets were calculated using the statistical tool at 
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http://www.fon.hum.uva.nl/Service/Statistics/RankCorrelation_coefficient.html, 
confirmed by additional statistical analysis at http://vassarstats.net/corr_rank.html.  
 
Cell proliferation assay 
AlamarBlue® cell viability reagent (Thermo Fisher Scientific) was used to estimate 
the cell numbers and the cell proliferation assay was performed according to the 
manufacturer’s protocol. Briefly, 1000 cells were seeded in each well of 96 cell well 
plates and were allowed to proliferate for 72 hours in regular culture media and 
conditions. AlamarBlue® cell viability reagent was added to the cells and incubated 
at 37°C for 1-4 hours. Infinite® M1000 spectrophotometer was used (Tecan US, 
Inc.) to read fluorescence at excitation wavelength 535 nm with emission wavelength 
at 595 nm. The readings were plotted with Y-axis showing the relative cell number.  
 
MDV3100 treatment 
 LNCaP-GFP, GRK3 and GRK3-KD cells were seeded in 24 well plates (4000 
cells per well, six replicates per cell line, per treatment). Cells were treated with 
vehicle or 5 μM MDV3100 for 10 days. Fresh media and drugs were replenished 
after 5 days of treatment. Cell viability was studied with the AlamarBlue® cell viability 
reagent (Thermo Fisher Scientific) as described above. 
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Chapter Three:  
GRK3 is a direct target of CREB activation and regulates 
neuroendocrine differentiation of prostate cancer cells 
 
 
This chapter is based upon  
Sang, M*., Hulsurkar M*., Zhang, X*., Song, H., Zheng, D., Zhang, Y., Li, M., Xu, J., 
Zhang, S., Ittmann, M.,Li, W.. GRK3 is a direct target of CREB activation and 
regulates neuroendocrine differentiation of prostate cancer cells. Oncotarget  
*These authors contributed equally.  
Published: May 14, 2016 Epub ahead of print.  
This content is licensed under a Creative Commons Attribution 3.0 License.   
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Background 
Neuroendocrine prostate cancer 
Progression to castration resistant prostate cancers (CRPC) is a major 
therapeutic challenge for prostate cancer patients. Unfortunately, the mechanisms 
underlying CRPC development remain largely unclear. Approximately 25% of men 
who die of prostate cancer have tumors with a neuroendocrine phenotype56,99-101. 
Neuroendocrine prostate cancer (NEPC) is characterized by loss of androgen 
receptor (AR) expression, resistance to hormonal therapies, and elevated levels of 
NE-related proteins, such as enolase 2 (neuronal, ENO2) and chromogranin A and 
B (CHGA/CHGB56,99-101. NEPC is associated with aggressive disease, frequent 
metastases to soft tissues and a short survival time11-13,15,16. With the recent 
introduction of potent ADT drugs, such as enzalutamide and abiraterone acetate, the 
incidence of NEPC is expected to increase dramatically56-59,99,102,103. A better 
understanding of the molecular events underlying NEPC development is urgently 
needed to develop a therapeutic solution for CRPC/NEPC.   
NEPC can arise de novo, but most commonly evolves from preexisting 
prostate adenocarcinoma (PAC)93,104-106. The majority of evidence to date favor a 
transdifferentiation model of NEPC origin, where PAC treated extensively with 
androgen deprivation therapy (ADT) or radiation therapy develop into NEPC, as a 
mechanism of adaptive response and drug resistance14-16,46-48,54,81-86,93,105-108. 
Recently, neuroendocrine differentiation (NED) has been observed in a patient-
derived xenograft model of prostate adenocarcinomas that developed NEPC after 
medical castration103,109,110.  
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cAMP response element-binding protein (CREB)  
CREB is a transcription factor that binds to DNA at cAMP Response Element 
(CRE) site.  Multiple stimuli induce CREB activation, resulting into myriad of 
responses like neuronal signaling, cell growth and motility etc111. CREB 
phosphorylation at S133 results into its activation46,47,82,83  and many upstream 
kinase regulators, including PKA, are responsible for CREB activation111 (Fig. 3.1). 
All the CREB target genes share an upstream CRE sequence of TGANNTCA, the 
binding site where CREB interacts with DNA112,113.  More than 100 genes are 
reported to be targeted by CREB111. It is still unclear how this complex network of 
multiple upstream kinase regulators and hundreds of target genes is regulated with 
specificity (Fig. 3.2), suggesting that the underlying mechanisms of CREB 
transcription regulation are not completely understood.   
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Figure 3.1. An Overview of signaling pathways that converge on CREB 
Excitatory neurotransmitters, ligands for GPCRs, neuronal growth factors, and stress 
inducers are among the stimuli that activate signaling pathways that converge upon 
CREB. As described in the text, multiple stimulus-dependent protein kinases have 
been implicated as CREB kinases in neurons, and a high degree of crosstalk exists 
between these signaling pathways. Stimulus-dependent CREB kinases include PKA, 
CaMKIV, MAPKAP K2, and members of the pp90RSK (RSK) and MSK families of 
protein kinases. Protein phosphatase 1 (PP1) has been implicated as the 
predominant phospho-CREB phosphatase111,114,115.  
Taken with permission from Lonze, B.E., Ginty, D.D. Function and Regulation of CREB 
Family Transcription Factors in the Nervous System. Neuron. Volume 35, Issue 4, 2002, 
605–623. 
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Figure 3.2. CREB-dependent gene expression is critical for a variety of 
functions. 
Shown are some of the processes for which CREB-dependent gene expression has 
been implicated. Stimuli and conditions that promote CREB phosphorylation and 
CREB-mediated gene expression are indicated in the upper half of the diagram, 
while physiological and pathological consequences of CREB activation are depicted 
in the lower half. 
Taken with permission from Lonze, B.E., Ginty, D.D. Function and Regulation of CREB 
Family Transcription Factors in the Nervous System. Neuron. Volume 35, Issue 4, 2002, 
605–623. 
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GRK3 
GRK3 belongs to the subfamily of G-protein coupled receptor kinases 
(GRKs). GRKs are best known for their roles in the phosphorylation and 
desensitization of agonist-bound GPCRs116-120, including beta-adrenergic receptors 
(ADRBs). ADRBs act through the increase of cAMP by adenylyl cyclase (AC) and 
activation of PKA/CREB pathway121-123. Therefore, PKA/CREB can be activated 
through ADRB stimulation (such as isoproterenol)121, or by a direct activator of AC, 
forskolin (FSK) and the inhibitor of phosphodiesterase, IBMX124.  
Through unbiased shRNA and cDNA screening of hundreds of human 
kinases, our lab has previously shown that G-protein coupled receptor kinase 3 
(GRK3) is a new critical activator of prostate cancer progression91. Not only is it 
necessary for the survival and proliferation of metastatic cancer cells in vitro and in 
vivo, but it is also sufficient to promote primary tumor growth in the prostate and 
metastases in soft tissues. Notably, GRK3 is overexpressed in human prostate 
tumors, especially in soft tissue metastases91. However, it is unknown what 
biological processes are responsible for GRK3 overexpression in prostate cancers 
and how GRK3 contributes to prostate cancer progression.  
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Working hypothesis 
Our working hypothesis is that activated by ADT, CREB induces GRK3 
expression and GRK3 acts as a mediator of CREB to induce neuroendocrine 
differentiation of prostate cancer cells.  
To understand how GRK3 and NEPC progression contribute to poor 
prognosis in prostate cancer, we investigated the mechanisms of GRK3 
overexpression in prostate cancer and its connections to ADT, CREB activation and 
NEPC development. We show that GRK3 indeed controls NED phenotypes of 
prostate cancer cells, and is induced by ADT as a direct target and critical mediator 
of CREB activation. These results elucidate the mechanisms of NED in prostate 
cancer cells and may facilitate establishment of GRK3 as a new therapeutic target 
for NEPC. 
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Results  
ADT induces neuroendocrine differentiation of human prostate 
adenocarcinoma LNCaP cells. 
To investigate the signaling pathways and molecular mechanisms of 
neuroendocrine prostate cancer cells, we compared the classic AR-positive 
adenocarcinoma (PAC) LNCaP cells with NE1.3 cells, neuroendocrine differentiated 
NEPC cells derived from LNCaP cells through long term androgen deprivation 
treatment (ADT)48,93. As shown in Fig. 3.3 A, LNCaP cells have an epithelial 
morphology, whereas NE1.3 cells show a neuronal morphology with rounded cell 
bodies and extended, finely branched processes. NE1.3 cells expressed low levels 
of AR and AR target PSA, and high levels of NE markers CHGA, CHGB and ENO2 
(Fig. 3.3 B-C). This is consistent with the literature that long term ADT induces NED 
in PAC cells, mouse models and patients14,82,93,100,104,105,125-127. In addition, we 
observed that the expression of NE markers was significantly higher in another 
NEPC cell line NCI-H660 than in PAC cell line LNCaP128 (Fig. 3.3 D).  
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Figure 3.3. Androgen deprivation treatment (ADT) induces neuroendocrine 
differentiation in prostate cancer cells. (A) Representative images show that 
prostate adenocarcinoma cells LNCaP have an epithelial morphology, whereas the 
ADT-induced LNCaP-derived neuroendocrine cancer cells NE1.3 show a neuronal 
morphology with compact, rounded cell bodies and extended, finely branched 
processes. (B) RT-PCR shows the expression patterns of androgen receptor (AR) 
and AR target, prostate specific antigen (PSA), in LNCaP and NE 1.3 cells. Y-axis 
shows the relative fold differences in expression, normalized to GAPDH. (C, D) RT-
PCR shows the expression patterns of neuroendocrine markers chromogranin A and 
 
 
38 
 
B (CHGA, CHGB) and enolase 2 (ENO2) in NE1.3 (C) and NCI-H660 (D) as 
compared to LNCaP cells. Y-axis shows the relative fold differences in expression, 
normalized to GAPDH.  Results in this figure were obtained in collaboration with 
Sang M and Zhang XC.  
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GRK3 is up-regulated in ADT-induced NEPC cells. 
 We hypothesized that GRK3 promotes NEPC development. Indeed, we found 
that GRK3 was significantly up-regulated in NEPC cells NE1.3 and H660 at both 
mRNA and protein levels as compared with the PAC cells LNCaP and VCaP (Fig. 
3.4 A-B). By analyzing data from a time course study of androgen deprivation of 
LNCaP cells (GSE8702)129, we found a similar result, i.e. GRK3 and NE marker 
ENO2 are up-regulated as the LNCaP cells become androgen-independent after 
long term ADT (Fig. 3.5).  To mimic castration-induced neuroendocrine 
differentiation in vivo, we compared the expression of GRK3 and NE markers 
between untreated PAC prostate cancer patient-deprived xenograft (PDX) LTL331 
and NEPC PDX LTL331R that derived from LTL331 after relapse from 
castration103,109,110,130. GRK3 and NE markers (ENO2, CHGA and CHGB) are 
significantly up-regulated in LTL331R (Fig. 3.4 C). 
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Figure 3.4. GRK3 is up-regulated in neuroendocrine prostate cancer (NEPC). 
Western blot assays (A) and RT-PCR (B) comparing the expression of GRK3 in 
prostate adenocarcinoma (PAC) cells LNCaP and VCaP to NEPC cells NE1.3 and 
NCI-H660. Y-axis: relative differences in expression normalized to GAPDH. (C) 
GRK3 is significantly up-regulated when the prostate cancer patient derived 
xenograft (PDX) PAC model LTL331 tumors relapsed after castration and become 
CRPC/NEPC (LTL331R). RNA-seq data by Akamatsu S et al130 were obtained and 
analyzed for GRK3 expression. Y-axis indicates the log2 of the expression levels. 
(D) Expression of GRK3 in different genetically engineered mouse (GEM) models of 
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prostate cancer (GSE53202). TRAMP mice are a classic GEM model for NEPC 
while Hi-Myc mouse is a classic model of prostate adenocarcinoma (PAC). Y-axis 
shows the normalized and transformed expression values in the indicated data sets 
obtained from the GEO database (B and D). Results in this figure were obtained in 
collaboration with Sang M and Zhang XC.  
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To further strengthen these results from human prostate cancer cells and PDX 
models, we investigated GRK3 expression in a classic NEPC genetically engineered 
mouse (GEM) model, the TRAMP mouse131,132. Analysis of microarray data in 
GSE58822 and GSE53202133,134 revealed GRK3 levels were significantly higher in 
prostate tumors of the TRAMP mice than in normal prostate tissues of wild type mice 
(P=0.0043 in GSE58822 and P=2.17E-16 in GSE53202) (Fig. 3.4 D). Interestingly, 
GRK3 is also expressed more highly in tumors of the TRAMP mice than in a classic 
GEM model for PAC, the Hi-Myc mice (P=1.02E-6, GSE53202) (Fig. 3.4 D). All 
together, these results show that GRK3 is induced by ADT and up-regulated in 
NEPC.  
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Figure 3.5. GRK3 and ENO2 expressions are up-regulated upon androgen 
deprivation. Results from data mining of a time course study of androgen 
deprivation of LNCaP cells (GSE8702). Y-axis shows the log2 transformed 
expression of GRK3 and NE marker ENO2 at different durations of androgen 
deprivation of LNCaP cells (untreated; early, 3 week-1 month; midterm, 5 months; 
late, 12 months).  Results in this figure were obtained in collaboration with Li W.  
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GRK3 is a direct target of CREB activation that is induced by ADT. 
Consistent with reports in literature that CREB activation promotes NED in prostate 
cancer cells85,86,135, we found that CREB was up-regulated and activated (by pS133 
level136-138) in NEPC cells NE1.3 and H660 (Fig. 3.6 A-B). Moreover, overexpression 
of either the CREB wild type cDNA or constitutively active mutant CREB-Y134F 
cDNA increased the expression of NE markers and GRK3 in prostate cancer cells 
(Fig. 3.6 C-D).  
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Figure 3.6. CREB activation is induced by androgen deprivation treatment 
(ADT) and promotes neuroendocrine differentiation of prostate cancer cells. 
(A) Western blots show that CREB is up-regulated and hyper-phosphorylated at 
S133 (activated) in ADT-induced NE1.3 and in NCI-H660 cells, as compared to 
LNCaP and VCaP cells. (B) RT-PCR shows elevated expression of CREB in NEPC 
NE1.3 and NCI-H660 cells compared to LNCaP and VCaP cells. Y-axis shows the 
relative fold differences in expression, normalized to GAPDH. (C) A Western blot 
shows overexpression of flag-tagged wild-type and constitutively active Y134F 
mutant of CREB. (D) RT-PCR shows elevated expression of NE markers CHGA, 
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CHGB and ENO2 in the prostate cancer cells overexpressing flag-tagged wild-type 
or constitutively active Y134F mutant of CREB. Y-axis shows the relative fold 
differences in expression, normalized to GAPDH.  Results in this figure were 
obtained in collaboration with Sang M and Zhang XC.  
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CREB-Y134F contains a mutation in which tyrosine 134 is changed to 
phenylalanine, which increases its affinity to PKA, and thus enhances its 
phosphorylation and activation by PKA95. Induction of GRK3 was also observed 
when we treated prostate cancer cells with beta-adrenergic receptor agonist 
isoproterenol (ISO), or adenylyl cyclase activator forskolin (FSK) with 
phosphodiesterase inhibitor IBMX (FSK+IBMX) (Fig. 3.7 B, Fig. 3.8 B). Both 
treatments are known to activate CREB through PKA phosphorylation at S133137-141. 
These results support our hypothesis that GRK3 is induced by CREB activation.  
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Figure 3.7. GRK3 is a direct transcriptional target of CREB activation. (A) 
Western blot shows that GRK3 expression is up-regulated in prostate cancer cells 
overexpressing CREB-WT and CREB-Y134F cDNAs. (B) PC3 and LNCaP cells 
were treated with 10 μM isoproterenol (ISO, beta-adrenergic receptor agonist), or 10 
μM forskolin (FSK, adenylyl cyclase activator) + 0.5 mM IBMX (phosphodiesterase 
inhibitor) for 4 hours. Western blot analysis shows that CREB was hyper-
phosphorylated at S133 and GRK3 was significantly up-regulated in both LNCaP 
and PC3 cells upon treatment with ISO or FSK+IBMX. (C) Two consensus cAMP 
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response element (CRE) sites, TGANNTCA, are located ~2000 bp upstream of the 
transcription initiation site in GRK3 promoter. (D) PC3 and RWPE1 cells were 
treated with 10 μM ISO or 10 μM ISO+propranolol (PRO, beta-adrenergic receptor 
antagonist). Chromatin immunoprecipitation (ChIP) was done with anti-CREB and 
anti-IgG antibodies, followed by PCR using primers designed to recognize the GRK3 
promoter sequence around the CRE sites. The ChIP-PCR results were confirmed by 
DNA gel electrophoresis, using inputs as loading controls. The quantitative 
measurements of CREB binding to GRK3 promoter are shown in Fig. 3.9. Results in 
this figure were obtained in collaboration with Sang M and Zhang XC.  
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We further found two consensus cAMP response element (CRE) sites on GRK3 
promoter (Fig. 3.7 C), which suggests that GRK3 is a direct transcriptional target of 
CREB activation. To confirm that CREB directly binds to GRK3 promoter, we carried 
out chromatin immunoprecipitation (ChIP) assay in PC3 and RWPE1 cells. The 
specific binding of CREB to GRK3 promoter was significantly increased after ISO 
treatment, and inhibited by beta-adrenergic receptor antagonist propranolol (PRO)142 
(Fig. 3.7 D, Fig. 3.9). These results indicate that GRK3 is a direct target of CREB 
activation.  
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Figure 3.8.  GRK3 expression is up-regulated upon CREB activation at mRNA 
level. (A) RT-PCRs showing the expressions of CREB and GRK3 in PC3 cells 
overexpressing CREB cDNA. GRK3 expression is up-regulated in cells 
overexpressing CREB. (B) PC3 cells were treated with CREB activator forskolin 
(FSK, 10 μM, 4 hours). GRK3 expression was up-regulated in cells treated with FSK. 
Y-axis shows the relative fold differences in expression, normalized to GAPDH.  
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Figure 3.9.  CREB binds to GRK3 promoter.  The ChIP-PCR results were 
quantified for Fig. 3.9 as % binding of the input and plotted on the Y-axis. PC3 and 
RWPE1 cells were treated with 10 μM ISO (isoproterenol, beta-adrenergic activator) 
or 10 μM ISO + 10 μM PRO (propranolol, beta-adrenergic receptor antagonist). 
Chromatin immunoprecipitation (ChIP) was done with anti-CREB and anti-IgG 
antibodies, followed by PCR using primers designed to recognize the GRK3 
promoter sequence around CRE sites.  
  
 
 
53 
 
GRK3 expression positively correlates with CREB and NE markers in human 
cancer tissues and cell lines. 
Our results reveal that GRK3 is a direct target of CREB, which suggests a positive 
correlation between CREB and GRK3 expression in human cancer cells and tissues. 
Indeed, mRNA expression of CREB and GRK3 are positively correlated in several 
widely cited prostate cancer datasets, such as Yu_PCa143 (GSE6919), 
Taylor_PCa144 (GSE21034) and TCGA_PCa (obtained from 
www.cBioPortal.org42,98), with Pearson correlation coefficients r = 0.36, 0.44 and 
0.52, respectively, and P<0.000001 for all three (Fig. 3.10 A). Furthermore, we 
carried out analysis of the levels of GRK3 protein and CREB activation (by pS133-
CREB) in a tissue microarray with 78 cases of human prostate cancer and normal 
samples. The p-CREB level was found to positively correlate with the expression of 
GRK3 (Chi Square χ2 = 22.2, P=0.0002) (Fig. 3.10 B and Table 3.1). These results 
support our finding that GRK3 is a target of CREB activation and suggest that the 
CREB/GRK3 axis is active in human prostate tissues.  
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Figure 3.10. GRK3 expression positively correlates with CREB expressions. 
(A) Results from data mining of published prostate cancer datasets Yu_PCa, 
Taylor_PCa and TCGA_PCa for mRNA expressions of CREB and GRK3. CREB and 
GRK3 expressions positively correlate with each other, with Pearson correlation 
coefficients r = 0.36, 0.44 and 0.52, respectively, and P<0.000001 in all three 
datasets. (B) Immunohistochemistry staining was performed on a tissue microarray 
with 78 cases of human prostate cancer and normal samples using anti-GRK3 and 
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anti p-CREB (S133) antibodies. Staining results in each sample were scored 
according to the staining area and staining intensity on a scale of 1 to 3. Two 
representative tumor cases are shown. Results in this figure were obtained in 
collaboration with Sang M and Zhang XC.  
 
 
 Table 3.1. Results of IHC staining of tissue microarrays with 78 cases of 
human prostate cancer and normal samples. Chi-square test showed that p-
CREB levels positively correlate with the expression of GRK3 (Chi Square χ2 = 22.2, 
P=0.0002) 
 
 
  
 
p-CREB 
GRK3 
+ (1) ++ (2) +++ (3) 
+ (1) 22 7 1 
++ (2) 7 9 5 
+++ (3) 4 14 9 
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To determine if the positive correlation between CREB and GRK3 exists beyond 
prostate cancer, we analyzed their expression patterns in ~1000 human cancer cell 
lines from the Cancer Cell Line Encyclopedia (CCLE)145. GRK3 expression indeed 
positively correlates with CREB expression (Pearson correlation coefficient r = 0.43, 
P<0.000001) (Fig. 3.11 A). To test whether GRK3 expression correlates with the 
expression of NE markers as well, we analyzed the CCLE cancer cell lines with 
measurable CHGA or CHGB expression (log2 transformed expression >4) and 
found that GRK3 expression positively correlates with CHGA (r = 0.41, P<0.00001) 
and CHGB expressions (r = 0.24, P<0.00001) (Fig. 3.11 B). These results suggest 
that positive correlation between GRK3 and NED markers exists broadly in human 
cancer cell lines.  
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Figure 3.11. GRK3 expression positively correlates with CREB and NE marker 
expressions. (A) GRK3 expression positively correlates with CREB expression in 
~1000 human cancer cell lines from the Cancer Cell Line Encyclopedia (Pearson 
correlation coefficient r = 0.43, P<0.000001). (B) GRK3 expression positively 
correlates with CHGA and CHGB expression in human cancer cell lines from the 
Cancer Cell Line Encyclopedia (P<0.00001 in both). Only cell lines with meaningful 
CHGA or CHGB level (log2 expression >4) were included in this analysis. The 
normalized and transformed expression values downloaded from GEO database or 
www.cBioPortal.org were used in our analysis and are plotted on X and Y-axes: 
normalized expression values for Yu_PCa, Z-scores of expression for TCGA_PCa, 
log2 transformed expression in all other scatter plots. Results in this figure were 
obtained in collaboration with Li W.  
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GRK3 is a critical activator for NE phenotypes of prostate cancer cells. 
Upon showing that GRK3 is up-regulated in NEPC as a direct target of CREB 
activation, we next investigated whether GRK3 plays a critical role in promoting NED 
induced by ADT or CREB activation. Consistent with the literature47,83, LNCaP cells 
developed features of neuronal morphology upon CREB activation by FSK+IBMX 
treatment (Fig. 3.12 A). As expected, the treatment also significantly increased 
expressions of NE markers CHGA, CHGB and ENO2 (Fig. 3.12 B, Fig. 3.13). We 
simultaneously carried out the same FSK+IBMX treatment on LNCaP cells 
expressing GRK3 shRNA# 1 or shRNA# 2 (Fig. 3.12 C-D). Notably, FSK+IBMX 
could no longer induce the expression of NE markers and obvious NE morphology 
upon GRK3 knockdown (Fig. 3.12 C-D). These results indicate that GRK3 is 
required for NED induction by CREB activation in LNCaP cells. 
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Figure 3.12. GRK3 is critical for CREB induced neuroendocrine differentiation 
of prostate cancer cells. (A) LNCaP cells exhibited a typical epithelial, fusiform 
morphology,  tapering into unbranched processes typically less than one cell body 
length, whereas FSK+IBMX treatment (10 μM FSK + 0.5 mM IBMX) treatment 
resulted in a neuronal morphology with compact, rounded cell bodies and extended 
numerous long, fine, branched processes with defined growth cones. (B) RT-PCR 
comparing the expressions of NE markers CHGA, CHGB and ENO2 in the mock or 
FSK+IBMX treated LNCaP cells. Y-axis shows the relative fold differences in 
expression, normalized to GAPDH. (C)RT-PCR results show that the expressions of 
CHGA, CHGB and ENO2 could not be up-regulated with FSK+IBMX upon GRK3 
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down-regulation in LNCaP cells. Y-axis shows the relative fold changes in 
expression, normalized to GAPDH. (D) Representative images of LNCaP cells that 
express either Scramble control shRNA or two specific GRK3 shRNAs after 
treatment with either DMSO vehicle or forskolin (FSK, 10uM) for 4 ours. The GRK3 
knockdown efficiency in LNCaP-shGRK3 cells is shown in Supplemental Fig. S6A. 
Results in this figure were obtained in collaboration with Sang M and Zhang XC.  
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Figure 3.13.  NE-marker expressions are up-regulated at protein level. (A) 
LNCaP cells were treated with CREB activator forskolin (FSK, 10 μM, 4 hours) and 
0.5 mM IBMX (phosphodiesterase inhibitor, 4 hours). A western blot shows that 
treatment with forskolin and IBMX (FSK+IBMX) results in the higher expression of 
NE marker CHGA. (B) Overexpression of GRK3, but not its kinase-dead mutant 
GRK3-KD, results in the up-regulation of NE markers CHGA and ENO2 in LNCaP 
cells.  
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To evaluate whether GRK3 suppression is sufficient to reverse ADT-induced NED, 
we down-regulated GRK3 expression in ADT-induced NEPC cells NE1.3 using 
GRK3 specific shRNA91 (Fig. 3.14 B). As shown in Fig. 3.15 A, the expression of 
NE markers CHGA, CHGB and ENO2 were reduced upon GRK3 down-regulation. In 
addition, the neuronal morphology – small and rounded cell bodies, and extended, 
fine branches –disappeared (Fig. 3.15 B). Notably, GRK3 knockdown inhibited the 
proliferation of NE1.3 cells (Fig. 3.15 C).  
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Figure 3.14. GRK3 expression is altered with shRNA and cDNA. (A-B) Western 
blots confirming the down-regulation of GRK3 in LNCaP-shGRK3 and NE1.3-
shGRK3 cells. (C) RT-PCR confirming the overexpression of GRK3 in LNCaP-GRK3 
and LNCaP-GRK3 KD cells.  
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To further establish an essential role of the CREB-GRK3 axis in NED of prostate 
cancer cells, we next tested the hypothesis that upon GRK3 knockdown in NEPC 
cells, inhibition of CREB cannot further repress the expression of NE markers. 
Results from propranolol (PROP), an inhibitor of beta-adrenergic signaling and 
CREB activation, provide evidences supporting this hypothesis (Fig. 3.15 D).  This 
result, together with the data in Fig. 3.12 C-D, indicates that GRK3 is a key mediator 
of CREB activation in promoting NED of prostate cancer cells.   
Finally, to directly examine a causal role of GRK3 in NED of prostate cancer 
cells, we overexpressed GRK3 wild type (WT) cDNA and kinase dead (KD) cDNA 
with a K220R mutation91,146 in LNCaP cells (Fig. 3.14 C). GRK3-WT, but GRK3-KD 
does not, induced the expression of NE markers CHGA, CHGB, and ENO2, which 
suggests that the GRK3 kinase activity is required for its induction of NE markers 
(Fig. 3.15 E). Importantly, expressing GRK3-WT cDNA, rendered LNCaP cells more 
resistant to MDV3100 than expressing GFP control or GRK3-KD cDNA (Fig. 3.15 F). 
In addition, overexpressing GRK3 promoted LNCaP cell-derived primary tumor 
growth in vivo [37]. Collectively, these results indicate that GRK3 is a critical 
activator of NE phenotypes, ADT resistance, and progression of prostate cancer 
cells. 
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Figure 3.15. GRK3 controls neuroendocrine phenotypes of prostate cancer 
cells. (A) RT-PCR comparing the expressions of NE markers CHGA, CHGB and 
ENO2 in NE1.3 cells upon GRK3 down-regulation. Y-axis shows the relative fold 
differences in expression, normalized to GAPDH. (B) Representative pictures of 
NE1.3 cells expressing either Scramble control shRNA or GRK3 shRNA. Upon 
GRK3 down-regulation, the neuronal morphology of the NE1.3 cells (such as the 
compact, rounded cell bodies and extended and branched processes) disappeared. 
(C) NE1.3 cells with and without GRK3 down-regulation were seeded in 96 well 
plates and were allowed to grow for 72 hours (6 replicates). The cell numbers were 
measured using Alamar Blue® cell viability assay and the fold difference is plotted on 
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the Y-axis. (D) NE1.3 cells expressing Scramble or shGKR3 were either untreated 
(UT) or treated with beta-adrenergic receptor antagonist, propranolol (PROP, 
dissolved in H2O, 10 μM, 4 hours), followed by western blotting analysis for 
expression of NE markers synaptophysin (SYP) and tubulin-beta III (TUBB3)147,148.  
(E) RT-PCR comparing the expression of NE markers in LNCaP cells upon 
overexpression of GFP, GRK3 (wild-type) or GRK3-KD (kinase dead) cDNA. Y-axis 
shows the relative fold differences in expression, normalized to GAPDH. (F) LNCaP-
GFP, LNCaP-GRK3 and LNCaP-GRK3-KD cells were treated with DMSO vehicle or 
5uM MDV3100 (enzalutamide) for 10 days. The cell numbers were measured using 
Alamar Blue® cell viability assay. The fold difference in viability in MDV3100 relative 
to DMSO for each cell lines are plotted on the Y-axis. P values were calculated 
using Student t-test, based on data from eight replicates. The GRK3 knockdown in 
NE1.3-shGRK3 cells and GRK3 overexpressing. Results in this figure were obtained 
in collaboration with Sang M and Zhang XC.  
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Summary 
In this study, we demonstrated that GRK3 is induced by androgen deprivation 
treatment (ADT) as a direct target of ADT-activated CREB, and that expression of 
GRK3 positively correlates with expression and activity of CREB in prostate cancer 
cells and tissues. Of note, overexpression of GRK3 is sufficient to promote 
neuroendocrine differentiation (NED) and resistance to MDV3100, while GRK3 
silencing blocks CREB-induced NED, reverses NE phenotypes, and inhibits 
proliferation of NEPC cells. These results suggest that ADT activates a critical 
signaling pathway, the CREB/GRK3 axis, in promoting NED of prostate cancer cells.  
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Chapter Four:  
Beta-adrenergic signaling promotes tumor angiogenesis 
and prostate cancer progression through HDAC2-mediated 
suppression of thrombospondin-1  
 
 
This work is based on  
Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer 
progression through HDAC2-mediated suppression of thrombospondin-1.  
Hulsurkar M, Li Z, Zhang Y, Li X, Zheng D, Li W. In press in Oncogene.  
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Background 
Chronic behavioral stress and cancer progression  
Behavioral stress and β-adrenergic signaling lead to cardiac hypertrophy and 
congestive heart failure (CHF)149,150, and have been increasingly associated with 
cancer progression18,23,151. Recently, it was shown that chronic behavioral stress and 
activated β-adrenergic signaling promote cancer progression in ovarian and prostate 
cancers18,23. The cAMP/PKA signaling pathway was shown to be necessary for 
behavioral stress mediated cancer progression18,23, through induction of 
angiogenesis in ovarian cancer23 and activation of a PKA/BAD anti-apoptotic 
signaling pathway in prostate cancer18. In addition, epidemiology studies on 
melanoma, breast, lung and prostate cancers indicated that cancer patients who 
took β-blockers, the hypertension drugs that interfere with signaling of the stress 
hormones adrenaline and noradrenaline, had better cancer clinical 
outcomes23,32,34,152,153.  
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Histone deacetylase 2 (HDAC2) 
Histone proteins bind to eukaryotic DNA to form nucleosomes, the basic structural 
unit that allows the DNA to be packaged into chromatins154,155. As a part of 
epigenetic regulation of gene expression, these histones are modified, changing the 
conformation of chromatin156,157. These modifications of histone, including 
methylation/de-methylation, acetylation/de-acetylation, control the extent to which 
the DNA is wrapped to histones156,157. Acetylation of histones results into more 
‘relaxed’ conformation, resulting into increased transcription of the target genes, 
whereas deacetylation results into gene silencing158. Histone deacetylates (HDACs) 
are a group of proteins that catalyze this reaction159. There are four classes of 
HDACs 160,161. Class I (HDACs 1, 2, 3 and 8) Class IIA and IIB (HDACs 4, 5, 6, 7, 9 
and 10) and Class IV (HDAC 11) form the classical family of HDACs160-162. 
Epigenetic regulation by HDACs is necessary for chronic behavioral stress to induce 
cardiac hypertrophy87-89. Specifically, HDAC2 has been implicated as a key mediator 
in this process90. However, it is not known whether and how HDAC2 acts as a 
downstream mediator of stress induced cancer progression.  
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Thrombospondin 1  
Thrombospondin 1 (TSP1) was the first identified endogenous inhibitor of 
angiogenesis163-165. TSP1 is a 140 KDa glycoprotein that was initially identified to be 
secreted from platelets166-168. TSP1 potently inhibits angiogenesis directly by 
interfering with endothelial cell migration and survival165,169.  TSP1 also acts as an 
antagonist for VEGF and inhibits its action through multiple pathways165,169 (Fig. 
4.1). Suppression of TSP1 results in increased angiogenesis165. Interestingly, TSP1 
is overexpressed upon treatment with HDAC inhibitors (HDACi) 170-172, suggesting 
that it is repressed by HDACs.  
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Figure 4.1 Schematic representation of the role of TSP-1 in the tumor 
microenvironment.  
 
Taken with permission from Patrick R. Lawler, and Jack Lawler Cold Spring Harb 
Perspect Med 2012;2:a006627. ©2012 by Cold Spring Harbor Laboratory Press. 
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Working hypothesis 
We hypothesize that activated by β-adrenergic signaling, CREB activates 
HDAC2 transcription and HDAC2 further represses TSP1 expression leading to 
induction of angiogenesis and cancer progression. In this study, we show that upon 
activation of the β-adrenergic signaling pathway, its downstream effector molecule, 
CREB, directly binds to the promoter of HDAC2 and induces its expression. HDAC2 
in turn suppresses TSP1 expression epigenetically, thus inducing angiogenesis and 
ultimately promoting β-adrenergic signaling-mediated prostate cancer progression.  
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Results 
Chronic behavioral stress induces tumor progression in vivo   
To investigate the mechanisms through which chronic behavioral stress 
promotes prostate cancer progression, we injected PC3 cells stably expressing 
luciferase into NOD/SCID mice and subjected the mice to chronic stress. The tumor 
growth was monitored non-invasively by imaging the luciferase-expressing tumor 
cells. After establishing the baseline of tumor growth, the mice were randomly 
divided into two groups – ‘calm’ and ‘stress’ groups. The stressed mice were 
subjected to behavioral stress by physically restraining their movement twice daily, 
for 1 hour. This periodic physical restraint system has been reported to induce 
chronic behavioral stress in mice23. After 25 days, the mice in the ‘stress’ group 
showed a 15.3-fold increase in the tumor size (measured by luminescence signal) 
compared to the 1.4-fold increase in the control ‘calm’ group (P = 0.02, Student’s t-
test) (Fig. 4.2).  
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Figure 4.2. Chronic stress promotes the growth of mouse xenografts of 
prostate cancer cells. Representative mice images showing that chronic behavioral 
stress promoted PC3 tumor growth in mouse xenografts. Luciferase labelled PC3 
cells were injected s.c. into both the flanks and shoulders of NOD/SCID mice. Three 
days after injection, the mice were randomly assigned to the undisturbed Calm 
group, or to the Stress group where the mice were subjected to restraint behavioral 
stress for one hour, twice a day for 25 days (n=12 tumors, 6 mice/group). 
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Activation of cAMP/PKA pathway downstream of the β-adrenergic receptors 
has been shown to mediate the effects of chronic behavioral stress in C4-2 prostate 
cancer xenograft models18. We next investigated whether activation of β-adrenergic 
signaling similarly induces xenograft tumor growth of prostate cancer cells PC3 and 
LNCaP. We used isoproterenol (ISO), a β-adrenergic receptor agonist, to stimulate 
β-adrenergic signaling173,174. Luciferase-expressing PC3 and LNCaP cells were 
injected into the mice. After establishing the baseline of tumor growth, the mice were 
divided into 2 groups. The control group received buffered saline; the ‘ISO’ group 
received 10 mg/kg ISO twice a day for 21 days (PC3 tumors) or 56 days (LNCaP 
tumors). Consistent with the literature23, the tumor growth was faster in the ISO 
treated group than in the control group (P = 0.04 for PC3 and P= 0.05 for LNCaP 
tumors, Student’s t-test) (Fig. 4.3a-b). Downstream of chronic stress/β-adrenergic 
receptor, CERB activation is responsible for ovarian cancer progression23. 
Therefore, we investigated whether the overexpression of constitutively active CREB 
promotes prostate cancer progression. We injected PC3 cells overexpressing CREB 
Y134F, a constitutively active CREB mutant, into NOD/SCID mice. We found that 
the tumor growth was faster in the mice injected with PC3 cells with CREB Y134F 
(P=0.02, Student’s t-test) (Fig. 4.3c). These results show that both chronic 
behavioral stress and activation of β-adrenergic signaling pathway promote tumor 
growth in xenograft mouse models for prostate cancer cells.  
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Figure 4.3. Chronic stress and the activation of β-adrenergic signaling 
promote the growth of mouse xenografts of prostate cancer cells. (a-b) 
Representative mice images showing that the activation of β-adrenergic signaling in 
mice promoted the growth of tumor xenografts for PC3 (a) and LNCaP cells (b). 
a 
b 
c 
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Mice were randomly assigned to receive either saline or  10 mg/kg ISO twice a day 
for 21 days (PC3, B) or 56 days (LNCaP, C) (n=12 tumors, 6 mice/group). The 
growth of each tumor was quantified using IVIS Lumina II platform. Fold increases 
on Y-axes were relative to day one. (c) Representative mice images showing that 
the overexpression of constitutively active CREB promoted the growth of tumor 
xenografts for PC3 cells. Luciferase labelled PC3 cells with or without 
overexpressing constitutively active CREB were injected s.c. into both the flanks and 
shoulders of NOD/SCID mice (n=12 tumors, 6 mice/group). Tumor growth was 
monitored for 21 days and fold increase for each tumor was calculated compared to 
day one.  
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Activation of β-adrenergic signaling induced angiogenesis  
Chronic stress has been shown to promote cancer progression by inducing 
tumor angiogenesis in ovarian carcinoma, which is mediated by β-adrenergic 
signaling23. We investigated if activation of β-adrenergic signaling by ISO treatment 
increased tumor angiogenesis in our xenograft prostate cancer models. Tumor 
tissues from control and ISO-treated mice were stained for Isolectin B4 (IB4), an 
angiogenic marker175,176. As shown in Fig. 4.4a, IB4 levels were elevated in tumors 
from ISO-treated mice, indicating an increase in angiogenesis. In addition to this in 
vivo finding, we evaluated the effects of activation of β-adrenergic signaling in 
prostate cancer cells on endothelial cell migration and tube formation, two commonly 
used in vitro angiogenesis assays177,178. Using conditioned medium from cancer 
cells to treat endothelial cells for studying their migration and tube formation abilities 
mimics the in vivo angiogenesis processes177. Conditioned media from PC3 cells 
treated with ISO increased the migration of SVEC4-10 cells, an endothelial cell line 
widely used for angiogenesis assays179 (Fig. 4.4b). In addition, SVEC4-10 cells 
formed more tubes (capillary-like structures), when incubated with conditioned 
medium from ISO-treated PC3 cells (Fig. 4.4c). Taken together, these data show 
that activation of β-adrenergic signaling in prostate cancer cells induces 
angiogenesis in vitro and in vivo.  
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Figure 4.4. Activation of β-adrenergic signaling induces angiogenesis. (A) A 
representative image for immunofluorescent (IF) staining of PC3 xenograft tumor 
tissues shows that ISO treatment increased the levels of IB4 (red), an endothelial 
marker and an indicator of angiogenesis. Tissue sections of multiple tumors from the 
untreated and ISO groups were stained for IB4. DAPI was used to visualize cell 
nuclei.  (B) SVEC endothelial cell migration assay. Conditioned media from 16 hours 
10 μM ISO treated or untreated PC3 cells were used to induce migration of serum-
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starved SVEC4-10 cells seeded on top of Boyden chambers. The assays were 
performed 3 times with similar results and the representative images are shown.  (C) 
SVEC endothelial cells tube formation assay. Conditioned media from 16 hours 10 
μM ISO-treated or untreated PC3 cells was used to culture serum-starved SVEC 
cells, seeded on growth factor reduced matrigel. The assays have been done at 
least 3 times with comparable results. All the results were confirmed by reproducing 
at least once.  
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HDAC2 is a downstream mediator of the β-adrenergic signaling induced 
angiogenesis  
Trivedi et al. showed that HDAC2 is critical for stress and β-adrenergic 
activation-induced congestive heart failure (CHF) 90. Whether β-adrenergic signaling 
directly regulates HDAC2 in CHF and whether this pathway is activated to promote 
cancer progression are unclear. Therefore, we next investigated the regulation of 
HDAC2 expression by β-adrenergic signaling and its role as a downstream mediator 
of the β-adrenergic signaling pathway in promoting angiogenesis. HDAC2 levels 
were found to be increased upon ISO activation of β-adrenergic signaling in PC3 
and DU145 cells (Fig. 4.5a). We then used LNCaP derived neuroendocrine prostate 
cancer cells NE1.393, in which CREB is hyper-phosphorylated (Fig. 4.5b, left), to 
study the effect of inhibition of CREB on HDAC2 expression. We inhibited CREB 
directly by protein kinase A inhibitor peptide 14-22 (PKI) as well as indirectly by β-
adrenergic receptor antagonists ICI118, 551(ICI) and propranolol (PRO). Protein 
kinase A phosphorylates CREB at S133 and activates it. Therefore, PKI treatment 
results into inactivation of CREB. On the other hand, ICI and PRO inhibit the β-
adrenergic signaling pathway, leading to inactivation of CREB. Upon treatments with 
these CREB inhibitors, HDAC2 was indeed downregulated (Fig. 4.5b, right). 
Moreover, HDAC2 expression was upregulated upon the overexpression of wild-type 
CREB cDNA and constitutively active mutant CREB-Y134F cDNA95  (Fig. 4.5c). In 
addition to these in vitro findings, activation of β-adrenergic signaling in vivo by ISO 
treatment in LNCaP xenograft tumors induced HDAC2 expression (Fig. 4.5d).  
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Figure 4.5. HDAC2 expression is upregulated upon activation of β-adrenergic 
signaling pathway. (A) PC3 and DU145 cells were untreated (UT), or treated with 
10μM isoproterenol (ISO, β-adrenergic receptor agonist), or 10 μM ISO + 10 μM 
propranolol (PRO, β-adrenergic receptor antagonist) for 4 hours. (B) Inhibition of 
PKA/CREB signaling in CREB-high NE1.3 cells led to HDAC2 downregulation. 
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LNCaP-derived neuroendocrine prostate cancer cells NE1.3 were untreated (UT), or 
treated with 10 μM PKI (PKA inhibitor), ICI 118 551 (ICI, β-adrenergic receptor 
antagonist) or PRO for 4 hours. Levels of HDAC2, total CREB, and pS133-CREB 
were measured by western blotting. (C) HDAC2 expression was elevated when wild-
type CREB or constitutively active mutant of CREB (CREB Y134F) was 
overexpressed in PC3 cells. (D) Quantitative RT-PCR result (top) shows that 
HDAC2 expression is upregulated in LNCaP xenograft tumors from mice treated 
with ISO. Y-axis shows the relative fold changes in expression, normalized to 
GAPDH. P-value was calculated using Student’s t-test. The PCR products were also 
analyzed by DNA gel electrophoresis (bottom). (E-G) Analyses of ~1000 human 
cancer cell lines in the CCLE database (E), the TCGA prostate cancer dataset (F), 
and metastatic prostate cancer samples by the SU2C/PCF Dream Team (G) 
42,98,180,181 showed that the expressions of HDAC2 and CREB are positively 
correlated. All the western blots results were confirmed by reproducing at least once. 
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Figure 4.6. Correlation between HDAC, CREB and TSP1 expressions.  (a-c) 
Analyses of ~1000 human cancer cell lines in the CCLE database (a), the TCGA 
prostate cancer dataset (b), and metastatic prostate cancer samples by the 
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SU2C/PCF Dream Team (c) 42,98,180,181 showed that the expressions of HDAC2 and 
CREB are positively correlated. All the western blots results were confirmed by 
reproducing at least once. 
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Since CREB is a key downstream effector of β-adrenergic signaling pathway, 
we postulated that CREB may directly regulate HDAC2 expression. Analysis of 
The Cancer Cell Line Encyclopedia (CCLE) database145 showed that CREB 
expressions are positively correlated with those of several HDACs in ~1000 human 
cancer cell lines, with HDAC2 having the strongest correlation with CREB 
expression (Spearman’s correlation Rho = 0.24 and P <= 8.2e-14) (Fig. 4.6a, and 
4.7a). In addition, according to the data obtained from cBioPortal for cancer 
genomics, HDAC2 and CREB expressions are also positively correlated in TCGA 
prostate cancers (Rho = 0.27, N = 487, P <= 1.9e-09, Fig. 4.6b)42,98,180,181 and in 
metastatic prostate cancer samples comprehensively analyzed by the SU2C/PCF 
Dream Team (Rho = 0.63, N = 118, P <= 6.6e-12, Fig. 4.6c)42,98,180,181. These 
correlations may appear relatively modest, with Rho = 0.24, 0.27 and 0.63, 
respectively. However, considering the large number of samples analyzed by these 
datasets and the heterogeneity of cancers, these correlations are significant.  
Interestingly, there are three full length CREB binding sites (TGANNTCA) at 
the HDAC2 promoter (Fig. 4.8a). To investigate if CREB binds to the HDAC2 
promoter at these putative CRE sites, we performed a ChIP-PCR assay by using 
anti-CREB, anti-pS133-CREB antibodies, and PCR primers designed from the 
HDAC2 promoter region harboring these CRE sites. CREB indeed bound to the 
promoter region of HDAC2 in PC3 and DU145 cells (Fig. 4.8b-c). Notably, the 
binding increased upon ISO treatment, and decreased with additional treatment of 
propranolol (PRO), an antagonist of β-adrenergic signaling. These results indicate 
that HDAC2 is a direct target of CREB transcriptional activation. 
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Figure 4.7. Correlation between HDAC, CREB and TSP1 expressions.  (a) 
Analysis of The Cancer Cell Line Encyclopedia (CCLE) database145 showed that 
CREB expressions are positively correlated with those of several HDACs in ~1000 
human cancer cell lines. Correlation between HDAC2 and CREB expressions is the 
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strongest (Spearman’s correlation Rho = 0.24 and P <= 8.2e-14). (b) Analysis of the 
CCLE database145 showed a strong negative correlation between TSP1 and several 
HDACs in ~1000 human cancer cell lines.  Correlation between HDAC2 and CREB 
expressions is the strongest (Spearman's rank correlation coefficient Rho= -0.31, P 
<1.38e-22).   
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Figure 4.8. CREB induces HDAC2 expression by binding to its promoter. (A) 
Three putative cAMP-response elements (CRE) in the promoter region of HDAC2. 
(B-C)  PC3 and DU145 cells were treated with 10 μM ISO, or 10 μM ISO + 10 μM 
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PRO for 4 hours. A ChIP assay was conducted using anti-CREB antibodies or IgG 
control, followed by PCR to amplify the HDAC2 promoter region around the putative 
CRE sites. The ChIP-PCR result was presented as % of the input, which was 
confirmed through DNA gel electrophoresis. All the ChIP results were confirmed by 
reproducing at least once. 
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We next determined whether HDAC2 acts as a critical downstream mediator 
for β-adrenergic signaling to promote cancer progression. We injected luciferase-
expressing PC3 cells, with/without stable HDAC2 knockdown (Fig. 4.9a), into 
NOD/SCID mice. After establishing the baseline of tumor growth, the mice injected 
with PC3-shHDAC2 cells were divided into 2 groups. The control group received 
buffered saline, the ‘ISO’ group received 10 mg/kg ISO twice a day for 21 days. 
Consistent with the literature23, the tumor growth was faster in the ISO treated group 
than in the control group (P = 0.005, Student’s t-test). However, ISO activated β-
adrenergic signaling was not able to induce tumor growth upon HDAC2 down-
regulation (P = 0.001, Student’s t-test) (Fig. 4.9b). To confirm the role of HDAC2 in 
mediating the effect of activated CREB overexpression in vivo, we injected PC3 cells 
overexpressing CREB Y134F, a constitutively active CREB mutant with stable 
HDAC2 knockdown, into NOD/SCID mice. We found that the tumor growth was 
slower in the mice injected with PC3 cells with both, CREB Y134F and HDAC2 
knockdown, compared to PC3 cells with only CREB Y134F overexpression. (P=0.02, 
Student’s t-test) (Fig. 4.9c). 
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Figure 4.9. HDAC2 is critical for tumor growth induced by β-adrenergic 
signaling. (A) Western blotting shows that both the HDAC2-shRNAs stably 
downregulated HDAC2 expression in PC3 cells. (B) Representative mice images 
showing that the activation of β-adrenergic signaling in mice could not promote the 
growth of tumor xenografts for PC3 cells with HDAC2 down-regulation. Mice were 
randomly assigned to receive either saline or 10 mg/kg ISO twice a day for 21 days 
(n=12 tumors, 6 mice/group). The growth of each tumor was quantified using IVIS 
Lumina II platform. Fold increases on Y-axes were relative to day one. (C) 
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Representative mice images showing that the overexpression of constitutively active 
CREB could not promote the growth of tumor xenografts for PC3 cells with HDAC2 
down-regulation. Luciferase labelled PC3 cells overexpressing constitutively active 
CREB with or without HDAC2 down-regulation were injected s.c. into both the flanks 
and shoulders of NOD/SCID mice (n=12 tumors, 6 mice/group). Tumor growth was 
monitored for 21 days and fold increase for each tumor was calculated compared to 
day one. 
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Further, we investigated whether HDAC2 acts as a critical downstream 
mediator for β-adrenergic signaling to induce in vitro angiogenesis. Conditioned 
media from prostate cancer cells treated with ISO, with and without HDAC inhibitor 
trichostatin A (TSA), were used in angiogenesis tube formation assay of SVEC4-10 
endothelial cells. Indeed, TSA treatment of PC3 cells inhibited the ISO-induced tube 
formation (Fig. 4.10a). Since TSA is a pan-HDAC inhibitor, to confirm the role of 
HDAC2, we next examined the effect on HDAC2 down-regulation on in vitro 
angiogenesis. Knockdown of HDAC2 expression by two independent HDAC2 
shRNAs in prostate cancer cells (Fig. 4.10b) abrogated the ISO-induced tube 
formation of SVEC4-10 cells (Fig. 4.10c). Taken together, these results indicate that 
CREB binds to HDAC2 promoter and induces its expression, and HDAC2 is critical 
in mediating the effect of β-adrenergic signaling on angiogenesis.  
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Figure 4.10. HDAC2 is critical for angiogenesis induced by β-adrenergic 
signaling. (A) PC3 cells were treated with 10 μM ISO with or without 0.3 μM 
Trichostatin A (TSA, HDAC inhibitor) for 16 hours in serum free media. Conditioned 
media from the PC3 cells were then used to culture serum starved SVEC cells 
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seeded on growth factor reduced matrigel for angiogenesis tube formation assay. (b) 
Conditioned media from ISO-treated PC3 cells expressing either scramble control 
shRNA or HDAC2-shRNA # 1 or #2 were used to culture serum-starved SVEC cells, 
seeded on growth factor reduced matrigel. Tube formation was quantified as number 
of nodes/branches per field, 3 fields per well, duplicates per sample. All the P-values 
were calculated using Student’s t-test. The assays have been conducted twice with 
comparable results.  
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β-adrenergic signaling suppresses the expression of anti-angiogenic protein 
TSP1 
Knowing that both HDACi treatment and HDAC2 down-regulation inhibit β-
adrenergic signaling induced angiogenesis, we hypothesized that HDAC2 represses 
some anti-angiogenic proteins. In a phase-2 clinical trial of HDACi Vorinostat 
(suberoylanilide hydroxamic acid, SAHA), it was shown that after 4 weeks of therapy 
with Vorinostat, reduction in the microvessel density in the patient tumors was 
correlated with the increased TSP1 expression171. TSP1 is also shown to be up-
regulated upon HDACi treatment in neuroblastoma, bladder and cervical cancer 
cells170-172. Therefore we were interested in determining if TSP1 is suppressed by 
the β-adrenergic signaling pathway to induce tumor angiogenesis and whether this 
suppression is mediated by HDAC2. Indeed, β-adrenergic signaling activators ISO 
and epinephrine (EPI) suppressed, while its inhibitors PRO and ICI118 551(ICI) 
induced, TSP1 expression in PC3, DU145 and LNCaP C4-2B prostate cancer cells 
(Fig. 4.11a). Treatment of neuroendocrine prostate cancer cells NE1.3 with CREB 
inhibitors inhibited CREB activation and induced TSP1 expression (Fig. 4.11b).  To 
further determine the role of CREB in TSP1 regulation, we overexpressed wild-type 
and constitutively active CREB in PC3 cells and observed that TSP1 levels were 
suppressed (Fig. 4.11c). 
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Figure 4.11. β-adrenergic signaling regulates TSP1. (A) PC3 and DU145 cells 
were treated with 10 μM ISO, or 10 μM ISO + 10 μM PRO for 4 hours, followed by 
western blotting for TSP1 protein expression. LNCaP C4-2B cells were treated with 
10 μM ISO, PRO, epinephrine (EPI, β-adrenergic receptor agonist), or ICI 118 551 
(ICI, β-adrenergic receptor antagonist) for 16 hours, followed by quantitative RT-
PCR assays. Y-axis shows the relative fold changes in expression, normalized to 
GAPDH. (B) LNCaP-derived neuroendocrine prostate cancer cells NE1.3 were 
treated with 10 μM PKI (PKA inhibitor), ICI or PRO for 4 hours to inhibit CREB 
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activation, followed by western blotting. (C) Western blotting shows that TSP1 
expression was down-regulated when wild-type CREB or constitutively active mutant 
of CREB Y134F was overexpressed in PC3 cells. 
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  Moreover, TSP1 expression was negatively correlated with CREB in ~1,000 
human cancer cell lines in the CCLE database145(Spearman's rank 
correlation coefficient Rho= -0.30, P <2.92e-20) (Fig. 4.12a). In addition to these in 
vitro findings, activation of β-adrenergic signaling suppressed TSP1 expression in 
LNCaP and PC3 mouse xenograft tumors (Fig. 4.12 b-c). To test whether TSP1 
suppression is critical for ISO induced in vitro angiogenesis, conditioned media from 
ISO-treated PC3 cells with or without added TSP1 peptides were used in tube 
formation assays of SVEC4-10 cells. We observed that the addition of TSP1 
peptides inhibited tube formation of SVEC4-10 cells induced by ISO treatment of 
PC3 cells (Fig. 4.13). These results indicate that activation of β-adrenergic signaling 
pathway suppresses TSP1 expression to induce angiogenesis.  
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Figure 4.12. β-adrenergic signaling regulates TSP1. (a) Analysis of ~1000 human 
cancer cell lines in the CCLE database showed that the expressions of TSP1 and 
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CREB are negatively correlated.  (b) Quantitative RT-PCR result (top) shows that 
TSP1 expression is down-regulated in LNCaP xenograft tumors from mice treated 
with ISO. PCR products were also analyzed by DNA gel electrophoresis (bottom). 
Activation of beta-adrenergic signaling suppresses TSP1 expression. A 
representative image for immunofluorescent (IF) staining of PC3 xenograft tumor 
tissues shows that ISO treatment suppressed the levels of TSP1 (green). Tissue 
sections of multiple tumors from the untreated and ISO groups were stained for 
TSP1. DAPI was used to visualize cell nuclei.   
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Figure 4.13. Suppression of TSP1 is necessary for β-adrenergic signaling to 
induce angiogenesis. 10 μM TSP1 peptides were added to the conditioned media 
from ISO-treated PC3 cells, which was then used to culture SVEC cells in tube 
formation assay. Representative images show that ISO treatment of PC3 cells could 
not increase SVEC tube formation in the presence of TSP1 peptides. Tube formation 
was quantified as number of nodes/branches per field, 3 fields per well, duplicates 
per sample. All the P-values were calculated using Student’s t-test. The assays have 
been conducted twice with comparable results.   
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Suppression of TSP1 by β-adrenergic signaling is mediated by HDAC2 
After establishing that the suppression of TSP1 expression is one critical 
mechanism through which the β-adrenergic signaling pathway induces 
angiogenesis, we tested if HDAC2 acts as a mediator for β-adrenergic signaling to 
suppress TSP1. Consistent with the literature170-172, HDAC inhibitor TSA induced 
TSP1 expression in PC3 cells (Fig. 4.14a). Notably, while ISO treatment alone 
suppressed TSP1 expression, ISO was unable to repress TSP1 expression in the 
presence of TSA (Fig. 4.14a). This indicates that HDACs act as critical mediators of 
β-adrenergic signaling pathway in regulating TSP1 expression.  
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Figure 4.14. Suppression of TSP1 by β-adrenergic signaling is mediated by 
HDAC2. (A) PC3 cells were treated with 10 μM ISO with or without 0.3 μM 
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Trichostatin A (TSA, HDAC inhibitor) for 24 hours. Western blotting results show 
that, while TSA and ISO alone induced and reduced TSP1, respectively, ISO was 
unable to suppress TSP1 in the presence of TSA. (B) Analysis of ~1000 human 
cancer cell lines in the CCLE database showed that the expressions of TSP1 and 
HDAC2 are negatively correlated. (C) Effects of HDAC2 downregulation on TSP1 
expression in CREB overexpressed PC3 cells.  While the overexpression of 
constitutively active CREB Y134F induced HDAC2 and suppressed TSP1 
expressions, downregulation of HDAC2 rescued the TSP1 repression by CREB. 
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We next investigated a specific role of HDAC2 in repressing TSP1 
expression. Analysis of the CCLE database145 showed a strong negative correlation 
between TSP1 and several HDACs, among which HDAC2 is the strongest one 
(Spearman's rank correlation coefficient Rho= -0.31, P <1.38e-22) (Fig. 4.14b and 
Supplementary Fig. 4.7b), which suggests that HDAC2 is a major HDAC repressing 
TSP1 expression. To identify the specific role of HDAC2, we down-regulated HDAC2 
in the PC3 cells overexpressing constitutively active CREB and observed that, while 
overexpression of constitutively active CREB suppressed TSP1 expression, down-
regulation of HDAC2 in these CREB-overexpressing PC3 cells restored TSP1 
expression (Fig. 4.14c). Upon confirming that HDAC2 acts as a mediator for β-
adrenergic signaling to repress TSP1 expression, we next investigated the 
mechanism through which HDAC2 regulates TSP1 expression. We observed strong 
histone H3K27 acetylation marks near TSP1 promoter in the UCSC Genome 
Browser (Fig. 4.15a), suggesting that HDACs may be repressing the TSP1 
expression by removing H3K27Ac activation marks on TSP1 promoter. ChIP-PCR 
assays were performed using anti-HDAC2 antibody to pull down HDAC2 bound 
chromatin and PCR using primers for the TSP1 promoter around these H3K27Ac 
marks. As expected, HDAC2 bound to the TSP1 promoter. Moreover, the interaction 
of HDAC2 with proteins binding directly to TSP1 promoter increased upon the 
activation of β-adrenergic signaling pathway by ISO treatment in PC3 and DU145 
cells, which was abrogated by additional treatment of β-adrenergic antagonist PRO 
(Fig. 4.15 a-b). These results indicate that HDAC2 epigenetically suppresses TSP1 
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expression and it acts as a critical downstream mediator of β-adrenergic signaling 
pathway in suppressing TSP1 and inducing angiogenesis. 
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Figure 4.15. HDAC2 binds to TSP1 promoter and suppresses its expression. 
(a) TSP1 gene promoter was visualized in the UCSC genome browser 
GRCh37/hg19 Assembly. A strong H3K27 histone acetylation mark was observed at 
the promoter region. A schematic of the original UCSC genome browser 
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GRCh37/hg19 assembly is shown. (b-c) PC3 and DU145 cells were treated with 10 
μM ISO, or ISO+PRO for 4 hours. A ChIP assay was conducted using anti-HDAC2 
antibody or IgG control, followed by PCR to amplify the TSP1 promoter region 
around the H3K27Ac mark. The ChIP-PCR result was presented as % of the input 
on Y-axis, which was further confirmed by DNA gel electrophoresis.  All the results 
were confirmed by reproducing at least once. 
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Summary 
  In summary, our study demonstrates that HDAC2 is a new target of CREB 
and HDAC2 induction is critical for tumor angiogenesis promoted by β-adrenergic 
signaling activation, which is mediated by HDAC2 suppression of TSP1. Taken 
together, these results support a new model, as illustrated in Fig. 8, that chronic 
stress and β-adrenergic signaling induce angiogenesis and prostate tumor growth, at 
least in part, through an unexpected role of CREB in directly inducing HDAC2 
expression that in turn epigenetically represses a potent anti-angiogenic protein, 
TSP1.  
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Chapter Five:  
Discussion 
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ADT, CREB, GRK3 and Neuroendocrine Prostate Cancer. 
Neuroendocrine prostate cancer causes approximately 25% of all the prostate 
cancer deaths56,99-101. It has been recognized that incidence of this aggressive 
variant of castration-resistant prostate cancer (CRPC) with neuroendocrine 
phenotype (NEPC) has been previously underestimated102  and a better 
understanding of the molecular events underlying NEPC development is urgently 
needed to develop a therapeutic solution for CRPC/NEPC.   
CREB activation has been shown to play a critical role in neuroendocrine 
differentiation (NED) of prostate cancer cells46,47,82-86. However, the downstream 
pathways and targets of CREB in NEPC cells are still incompletely understood. 
Here, we have demonstrated that GRK3 is expressed higher in cells and genetically 
engineered mouse (GEM) models of NEPC. Furthermore, GRK3 cDNA 
overexpression induces NE markers in prostate cancer cells in a kinase activity 
dependent manner, while its silencing reduces NE marker expression and reverses 
NE morphology in NEPC cells. These results indicate that GRK3 is a critical 
regulator for NEPC cells and that GRK3 contributes to prostate cancer progression 
at least in part by promoting the development of NEPC, an aggressive subtype of 
prostate cancers. 
Mechanistically, we found that GRK3 expression is induced by chemical 
activators of CREB or CREB cDNA overexpression. Further, a ChIP-PCR confirmed 
that CREB binds to GRK3 promoter and this binding of CREB changes in response 
to its activation and inhibition. On the other hand, silencing GRK3 abrogates CREB 
induction of NE markers in prostate cancer cells. Furthermore, GRK3 expression 
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has a positive correlation with CREB expression and activity in broad human cancer 
cell lines (CCLE) and human prostate cancer tissues. Together, these results 
establish that GRK3 is a direct target of CREB activation in prostate cancer cells.  
Previously, GRK3 has been shown to be up-regulated by chronic treatments with 
stress hormones, adrenaline and corticotropin release factor (CRF), in human 
neuroblastoma BE (2)-C cells and Y79 retinoblastoma cells. These two stress 
hormones are known to signal G-protein coupled receptors (GPCRs), beta 
adrenergic receptor (ADRB) and CRF1 receptor, and GPCR activation in turn leads 
to elevated cAMP levels. However, the mechanisms downstream of cAMP, and 
leading to GRK3 expression have not been studied before. We have addressed this 
question in our study, showing that downstream of stress and cAMP, CREB binds to 
GRK3 promoter and activates its expression. 
GRKs phosphorylate and desensitize GPCRs upon agonist stimulation. 
Therefore, up-regulation of GRK3 by adrenaline was considered as a negative 
feedback regulation to control the activation of beta adrenergic receptors and 
CREB182. However, for the first time, we have demonstrated that GRK3 is a critical 
mediator for ADRB2 activated CREB to induce neuroendocrine differentiation of 
prostate cancer cells. Furthermore, we also show a positive correlation between the 
expression of GRK3 and CREB in ~1000 cell lines of multiple cancer types. These 
results introduce a new paradigm that CREB/GRK3 axis mediates the effect of 
ADRB signaling and that it is active in many cancer types.  
Previously, our lab used unbiased shRNA and cDNA screening of hundreds 
of human kinases to show that GRK3 is a new critical activator of prostate cancer 
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progression91. It was found that GRK3 is necessary for the survival and proliferation 
of metastatic cancer cells in vitro and in vivo and, that it is sufficient to promote 
primary tumor growth in the prostate and metastases in soft tissues. Through 
immunohistochemistry staining for a large tissue array from human prostate cancer 
patients, it was shown that GRK3 is overexpressed in human prostate tumors, 
especially in soft tissue metastases91. Therefore, the data presented in our 
previous91 and current studies suggest that targeting GRK3 may be a viable 
approach to inhibit prostate cancer progression and NEPC development.  
Interestingly, the role of GRK3 in prostate cancer development is dependent 
on its kinase activity. While GRK3 suppressed the expression of tumor suppressors 
thrombospondin 1 (TSP1) and plasminogen activator inhibitor 2 (PAI2)91, the kinase-
inactive mutant of GRK3 could not suppress TPS1 and PAI2. In this study, we 
showed that the kinase-inactive mutant of GRK3 could not induce the NE marker 
expression in prostate cancer cells, suggesting that the GRK3 kinase activity is 
necessary to induce neuroendocrine differentiation. These results support the 
rationale to identify GRK3 kinase inhibitors as candidates for new cancer drugs. 
Kinases are known to be druggable183,184 and although there was initial 
skepticism about their specificity, highly selective small molecule kinase inhibitors 
have been successfully developed185. Several kinase inhibitors have been approved 
as cancer therapeutics186-190 and several hundred more are being studied as 
potential therapeutics 185,191. The greatest clinical success of these kinase inhibitors 
has been seen in cases where the inhibition of kinase activity has shown strong 
phenotypic changes e.g. cell survival192 or, reversal of NE phenotypes and reduced 
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proliferation, as we have shown97. An example of successful use of such kinase 
inhibitors was imatinib (Gleevec; Novartis)193  in treatment of chronic myelogenous 
leukemia (CML). This phenomenon, where cancer cells are dependent on an 
overexpressed/hyperactive gene is called oncogene addiction194. Our results show 
such dependency of neuroendocrine cells on GRK3 expression as well as its kinase 
activity. Therefore, we believe that GRK3 specific kinase inhibitors could be 
developed in future as a potential therapeutic against NEPC.  
Downstream mechanisms of GRK3, resulting in the expression of NE 
markers, have not been studied yet. Since GRK3 is a GPCR kinase, it may regulate 
a critical GPCR signaling pathway in NEPC development. In addition to GPCRs, 
GRKs are known to phosphorylate directly, or facilitate the phosphorylation of, non-
GPCR targets195-197. Role of GRK3 in NEPC progression could be understood future 
by further studying these possible mechanisms.  
Our results demonstrate that GRK3 is a new activator for neuroendocrine 
phenotypes and ADT resistance in prostate cancer cells. It is a direct target and a 
critical mediator of activated CREB in promoting NE differentiation. These results 
expand our knowledge of NEPC development, prostate cancer progression, and 
GRK3 as a prospective novel drug target for aggressive prostate cancers. 
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β-adrenergic signaling, CREB, HDAC2, TSP1 and Angiogenesis. 
β-adrenergic signaling activated by chronic behavioral stress has been shown 
to promote cancer progression and angiogenesis18,23,198. However, the downstream 
molecular effectors involved and their regulations of this pathway are still not 
completely known. In particular, the involvement of epigenetic regulation by HDACs 
in β-adrenergic signaling promoted cancer progression is unclear. While HDAC2 is 
shown to be necessary to mediate the effects of chronic stress in inducing cardiac 
hypertrophy90, how stress and the β-adrenergic signaling regulates HDAC2 and 
whether HDAC2 mediates stress promoted cancer progression are unknown.  
In this study, we have investigated the molecular bases of angiogenesis and 
cancer progression promoted by chronic stress and β-adrenergic activation in vitro 
as well as in xenograft mouse models. In particular, we have studied the role, 
regulation and mechanism of action of HDAC2 in these processes. We have 
demonstrated that β-adrenergic signaling up-regulates HDAC2 and down-regulates 
TSP1 expressions in vitro and in vivo in mouse xenografts. Downstream of β-
adrenergic signaling, CREB was uncovered to directly regulate HDAC2 expression. 
We have also demonstrated that epigenetic suppression of TSP1 by HDAC2 is 
critical for angiogenesis enhanced by β-adrenergic signaling.  
Our finding that CREB binds to HDAC2 promoter and induces its expression 
is intriguing. The current paradigm is that activated CREB recruits CREB binding 
protein (CBP) to activate transcription of its target genes199-203. Since CBP is a 
histone acetyltransferase (HAT), it is counterintuitive that CREB elevates HDAC2 
expression, because increased HDAC activity presumably counteracts CBP and 
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decreases CREB-dependent transcription. One possible explanation is that the 
induction of HDAC2 by CREB is a negative feedback regulation to control CREB-
activated transcription. However, our results support a new model, showing that 
HDAC2 is a critical mediator for CREB in TSP1 repression and enhancing 
angiogenesis. This is consistent with a study by Fass et al., showing that HDACs 
can either repress or enhance CREB activity by differentially regulating CREB target 
genes204. To further develop this new paradigm, it will be worthwhile in the future to 
examine the changes in global gene expression as well as in the CBP and HDAC2 
epigenetic landscapes upon the activation and inhibition of β-adrenergic signaling 
and PKA/CREB activation.  
 β-adrenergic signaling and activation of PKA/CREB pathways have been 
shown to promote angiogenesis through induction of VEGF in ovarian cancer cells23. 
Angiogenesis often involves changes in the levels of both pro-angiogenic and anti-
angiogenic proteins205-210. While ADRB2/PKA/CREB pathway was shown to induce 
the pro-angiogenic VEGF, it was unclear what anti-angiogenic proteins are 
repressed by β-adrenergic signaling. Our study contributes to filling this gap by 
demonstrating that β-adrenergic signaling represses a potent anti-angiogenic protein 
– TSP1. Interestingly, a few studies have demonstrated that TSP1 signaling, through 
its receptors CD36 or CD47, inhibits the PKA/CREB pathway in platelet activation as 
well as in T cells and breast cancer cells 211,212. With our finding that CREB 
represses TSP1 expression, an antagonism can be postulated between PKA/CREB 
and TSP1 signaling in certain biological processes.    
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HDAC inhibitors are being tested as anti-angiogenesis therapeutics213-216 and 
are reported to induce TSP1 expression. TSP1 expression is regulated largely at the 
transcriptional level and it has been established that HDAC inhibitors induce the 
expression of TSP1170-172,214,217,218. In the literature, it remained unclear how HDAC 
inhibitors (HDACi) induce TSP1 expression and no specific HDACs were implicated 
in TSP1 regulation170-172,214,217,218. Kang et al., have shown that CCAAT box in the 
promoter region of TSP1 is required for its induction upon treatment with TSA217. 
However, to our knowledge, this is the first study to report that HDAC2 binds to 
TSP1 promoter and represses its expression in prostate cancer cells. It remains to 
be determined if other HDACs also contribute to the CREB induction of 
angiogenesis and TSP1 repression. The global gene expression correlation between 
CREB and HDACs suggest that HDAC2 is one of the major HDACs involved, which 
is consistent with a critical role of HDAC2 in stress induced congestive heart 
failure90. In addition to TSP1 up-regulation, HDACi are shown to suppress the 
expression of VEGF and bFGF219. However, the mechanisms of this regulation are 
not clear.  Our finding that HDAC2 represses TSP1 expression by binding to its 
promoter expands our knowledge of the mechanisms of HDACi as angiogenesis 
inhibitors.  
Hassan S et al demonstrated that behavioral stress promotes prostate cancer 
progression through ADRB2/PKA/BAD pathway18. However, unlike Thaker PH et 
al23, no increased angiogenesis was observed in their stress-promoted prostate 
cancer model. As Hassan S et al pointed out, C4-2, the mouse model they used for 
the study, is highly vascularized and therefore, it was not possible to study the 
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increased angiogenesis18. Using different prostate cancer xenograft models (PC3 
and LNCaP), our data indicated that the CREB/HDAC2/TSP1 axis mediates the 
effect of β-adrenergic signaling on angiogenesis, which elucidates another critical 
mechanism underlying the activation of adrenergic signaling in promoting prostate 
cancer progression.  
These results advance established knowledge in the field of chronic 
behavioral stress, epigenetic regulation and prostate cancer progression. Future 
research will investigate the activation of the ADRB2/CREB/HDAC2/TSP1 pathway 
in human prostate cancer samples and determine whether TSP1 can be developed 
as a potential biomarker to monitor the efficacy of β-blocker or HDACi in cancer 
therapy. 
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Novel Mechanisms of β-Adrenergic Signaling in Prostate Cancer Progression. 
β-adrenergic signaling has been found to be responsible for the progression 
of breast19, colon and pancreatic20, lung21, skin22, ovarian23 cancers. Its inhibition by 
β-blocker use is correlated with better cancer prognosis24-34 and reduced cancer 
related mortality24-34. However, use of β-blockers to treat cancers has been limited 
due to lack of understanding of the underlying mechanisms. Therefore, mechanisms 
of β-adrenergic signaling in prostate cancer progression need to be studied further. 
Here, we have introduced two new pathways acting downstream of ADRB2/CREB 
axis. CREB/HDAC2/TSP1 pathway is responsible for induction of tumor 
angiogenesis, while CREB/GRK3 axis leads to tumor angiogenesis and 
neuroendocrine prostate cancer progression. We have introduced a new paradigm 
that β-adrenergic signaling and epigenetic gene expression regulation may be 
working synergistically resulting in cancer progression. The results from our study 
not only significantly advance current understanding of the pathways involved in β-
adrenergic signaling, but also provide with novel molecular candidates with 
therapeutic as well as biomarker potential.  
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Future Direction 
GRK3 has been shown to be a critical regulator for prostate cancer 
progression in a previous91 and our present97 study. We have also shown that GRK3 
expression is regulated by ADT-activated CREB, leading to neuroendocrine 
differentiation of prostate cancer cells. However, downstream mechanisms of GRK3 
are yet to be studied. Since the primary substrate of GRK3 is GPCRs, it is possible 
that it phosphorylates a GPCR involved in NEPC signaling. It is also possible that 
GRK3 phosphorylates a non-GPCR target or act as a scaffold to facilitate the 
interactions between a protein complex. In future, these mechanisms of GRK3 will 
be studied.  
Another direction for future work on CREB/GRK3/NEPC axis is the 
development of GRK3 kinase inhibitors as therapeutics. We have recently 
conducted a kinase inhibitor screen and have shortlisted highly potent GRK3 kinase 
inhibitors. We will study the effect of these inhibitors on prostate cancer progression 
in vitro and in vivo.  
We are preparing to use a large array of prostate cancer patient tissue 
samples to validate the CREB/HDAC2/TSP1 axis in human patients. We will perform 
immunohistochemistry/immunofluorescence staining to study the expressions and 
correlation between p-CREB, HDAC2 and TSP1 proteins. Based on the results from 
this study, TSP1 can be developed as a potential biomarker to monitor the efficacy 
of β-blocker or HDACi in cancer therapy in future. 
We will also study the changes in global gene expression as well as in the 
CBP and HDAC2 epigenetic landscapes upon the activation and inhibition of β-
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adrenergic signaling and PKA/CREB activation.  This study will uncover the 
mechanisms of synergy between epigenetic regulations by HDAC2 and CBP, new 
molecular regulators of ADRB2 signaling, as well as potential novel targets for 
development of new therapeutics or biomarkers.  
It has been shown recently that Epac-Rap1 pathway, activated by 
ADRB/camp, induce TSP1 expression in endothelial cells and fibroblasts220, 
independent of the PKA/CREB pathway. This suggests that β-adrenergic signaling 
induces TSP1 expression in endothelial cells and fibroblasts, while we have shown 
that the PKA/CREB pathway suppresses TSP1 expression in epithelial cells of 
prostate cancer. In future, we will study the synergy between these two regulations, 
which will reveal vital information about the role of tumor microenvironment in cancer 
progression.  
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